Page updated Jul 4, 2026 · using data updated on Jun 28, 2026
Obesity Clinical Trial Landscape
Obesity is a complex metabolic disorder characterized by excessive body fat accumulation that presents a significant health risk to individuals of all ages and backgrounds. The clinical trial landscape for obesity (metabolic) demonstrates substantial research activity, with 1,662 trials registered since 2008.
Currently, 495 trials are actively recruiting, enrolling, or active but not recruiting participants. The distribution of these active trials reveals a strong focus on early-stage development, with 140 active Phase 1 trials and 191 active Phase 2 trials, compared to 132 in Phase 3 and 84 in Phase 4.
Industry sponsorship is led by Eli Lilly, which has 50 active trials, followed by Novo Nordisk with 30. Other prominent sponsors include Amgen, Hangzhou Zhongmei Huadong Pharmaceutical Co., Ltd., and Innovent Biologics (Suzhou) Co. Ltd., with 10, 9, and 8 active trials, respectively.
The high volume of Phase 1 and 2 trials suggests a robust pipeline of novel therapeutic approaches in the early stages of evaluation.
Trial activity
518 active / 1,715 total since 2008
Active by phase 139 Ph3 / 388 174 Ph2 / 532 116 Ph1 / 445 89 Ph4 / 350
Competitive Intelligence
This Obesity competitive landscape maps 17 companies against 11 mechanisms of action (MOA) across 31 active drug-development programs, including 5 with a confirmed FDA PDUFA date. Each cell is the lead program for a company–mechanism pair — its trial phase, modality, combination, and nearest readout. Read down a column to see who is competing on the same mechanism in Obesity, across a row to see one company's mechanistic spread, and click any cell for the full program list and trial links.
Beta 17 companies 11 mechanisms 31 programs mapped 8 lowTrust (26%) 5 ⚖ PDUFA-dated ⏰ 12 due ≤6 mo click any cell → asset tearsheet
At a glance
Obesity shows 31 programs across 17 companies and 11 mechanisms. The most contested mechanism is GLP1R (30 programs).
Key findings
- 42% of GLP-1/GIP programs (8 of 19) are combos with novel agents — class-extension work, not class-validation.
- Top 3 mechanisms (GLP1R, GLP-1 receptor agonist, GLP-1/GIP) account for ~46% of programs — class concentration is moderate.
- Eli Lilly runs 46 programs — the deepest pipeline in this view.
- 40 hot readouts in next 6 months — most imminent: Eli Lilly (GLP1R).
- 28 trials are stale (overdue without status change) — possible class-maturity inflection or operational issue.
- 17 single-program mechanisms in the long tail — 9 are Ph2+ first-in-class first-mover bets.
- 9 NME candidates in the long tail.
- Most-novel-of-novel: Chendu DIAO Pharmaceutical Group GLP-1R agonist (Ph3) — first-in-class within scope + NME candidate.
Forward catalysts next 18 months⏰ 12 due ≤6 mo⚖ 5 PDUFA-dated
Nearest first. ⚖ Confirmed FDA PDUFA dates (curated calendar, primary sources) and 📅 estimated readouts (ClinicalTrials.gov
primaryCompletionDate — a timing proxy, not a confirmed action date). Red = due within 6 months.Company × Mechanism
Each cell = a company’s most-advanced program in that mechanism. Click for the asset tearsheet.
Select & Focus Pro → 🔒 Transpose, filtering, selection & export are Pro (search & sort are free) — start a free trial, or try them free on our showcase →
GLP1R | GLP-1/GIP | AMYLIN | GLP-1 receptor agonist | GLP-1/Amylin | GLP-1/GIP/glucagon | Glucagon-like peptide 1 receptor … | GLP-1/glucagon | Melanocortin receptor 4 agonist | Undisclosed target | Cyclooxygenase inhibitor | |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Eli Lilly | |||||||||||
| Novo Nordisk A/S | |||||||||||
| Amgen | |||||||||||
| 🇨🇳Innovent Biologics (Suzhou) | |||||||||||
| Rhythm | |||||||||||
| 🇨🇳Hangzhou Zhongmei Huadong | |||||||||||
| Structure | |||||||||||
| Verdiva Bio Dev Limited | |||||||||||
| 🇨🇳Beijing QL Biopharmaceutical | |||||||||||
| Gan & Lee Pharmaceuticals. | |||||||||||
| Regeneron | |||||||||||
| BrightGene Bio-Medical Techno… | |||||||||||
| 🇨🇳Fujian Shengdi | |||||||||||
| 🇨🇳Hangzhou Sciwind | |||||||||||
| Hudson | |||||||||||
| AstraZeneca | |||||||||||
| Roche / Genentech |
Phase 3 leaders · most advanced
- recruiting Novo Nordisk A/S NCT07339423
- recruiting Kailera NCT07284901
- recruiting Eli Lilly and Company NCT06937086
- recruiting Eli Lilly and Company NCT06937099
- recruiting Eli Lilly and Company NCT06672549
Beyond the grid Beta
What the matrix leaves out — rare mechanisms with only one player, small & emerging sponsors, and programs we haven’t classified yet.
Single-company mechanisms — BD white space 5 found
Mechanisms only ONE company is pursuing in this indication — the uncrowded / first-in-class bets the matrix cap hides. ⚡ first-in-class · ⚠ unverified mechanism. ⚡ first-in-class is computed across 61 mapped landscapes — scope-limited, not a global claim.
⚡ first-in-class · 🌱 first-in-indication · 🆕 NME candidate · ✅ AI-classified + verified · ⚙️ AI-classified, unverified · first-in-class computed across 61 mapped landscapes
Single-program mechanisms (17) — one program each — earliest-stage, sorted by phase
| Phase | Mechanism | Company | Modality | Readout | Trial |
|---|---|---|---|---|---|
| Ph3 | GLP-1 agonist ⚡ 🌱 | Carnot Laboratories | 4Q27 | NCT07622810 | |
| Ph3 | GLP-1R agonist ⚡ 🌱 🆕 | Chendu DIAO Pharmaceutica… | 3Q27 | NCT07629544 | |
| Ph3 | Neurokinin 1 receptor antagonist ⚡ 🌱 | Vanda | ⏰ 4Q26 | NCT07446439 | |
| Ph1+Ph2 | ALK7 ⚡ 🌱 🆕 | Arrowhead | ⏰ 4Q26 | NCT06937203 | |
| Ph2 | CB1 ⚡ 🌱 🆕 | Skye Bioscience | ⏰ 4Q26 | NCT06577090 | |
| Ph1+Ph2 | INHBE ⚡ 🌱 | Arrowhead | 3Q27 | NCT06700538 | |
| Ph2 | MAO-B (reversible) 🌱 🆕 | NeuroBiogen | Oral | 1Q27 | NCT07009171 |
| Ph1+Ph2 | MC4R ⚡ 🌱 🆕 | Rhythm | 4Q27 | NCT06239116 | |
| Ph2 | NPY2R ⚡ 🌱 🆕 | Eli Lilly | ⏰ 4Q26 | NCT06897475 | |
| Ph2 | Subtilisin/kexin type 9 inhibitor ⚡ 🌱 | Regeneron | ⏰ 4Q26 | NCT07477704 | |
| Ph1 | ATP-SENSITIVE POTASSIUM CHANNEL ⚡ 🌱 🆕 | AstraZeneca | ⏰ 3Q26 | NCT07444424 | |
| Ph1 | COX-2 ⚡ 🌱 | AstraZeneca | Oral | 3Q27 | NCT07013643 |
| Ph1 | HMGCR 🌱 | Roche / Genentech | ⏰ 4Q26 | NCT06982131 | |
| Ph1 | INSULIN RECEPTOR 🌱 🆕 | Gan & Lee Pharmaceuticals. | 3Q25 | NCT06974487 | |
| Ph1 | NPR1 agonist ⚡ 🌱 🆕 | Eli Lilly | ⏰ 3Q26 | NCT06148272 | |
| Ph1 | PROGESTERONE RECEPTOR/ESTROGEN RECEPTOR ⚡ 🌱 | AbbVie | SC | ⏰ 3Q26 | NCT07414784 |
| Ph1 | VKORC1 ⚡ 🌱 | Beijing QL Biopharmaceuti… | ⏰ 4Q26 | NCT07550816 |
Emerging & small-cap sponsors (17) — few programs here — partnering / M&A radar
| Phase | Mechanism | Company | Modality | Readout | Trial |
|---|---|---|---|---|---|
| Ph1+Ph2 | GLP-1/GIP | Alnylam | 2Q27 | NCT07463846 | |
| Ph2 | GLP1R ⚡ | Altimmune | ⏰ 2Q26 | NCT06987513 | |
| Ph2 | Glucagon-like peptide 1 receptor agonist ⚡ | Biophytis | 2Q27 | NCT07411378 | |
| Ph1 | Glucagon-like peptide 1 receptor agonist ⚡ | Boehringer Ingelheim | ⏰ 1Q27 | NCT06745284 | |
| Ph3 | GLP-1 receptor agonist ⚡ | Chia Tai Tianqing Pharmac… | ⏰ 3Q26 | NCT06738979 | |
| Ph1 | 🇨🇳 GLP1R ⚡ | CSPC Baike (Shandong) Bio… | ⏰ 3Q26 | NCT06830343 | |
| Ph2 | GLP1R ⚡ | Eccogene | ⏰ 4Q26 | NCT07505303 | |
| Ph3 | 🇨🇳 Glucagon-like peptide 1 receptor agonist ⚡ | Hangzhou Jiuyuan Gene Eng… | ⏰ 2Q26 | NCT06633783 | |
| Ph1+Ph2 | GLP-1/GIP | Ikaria Bioscience | 1Q27 | NCT07245771 | |
| Ph3 | Glucagon-like peptide 1 receptor agonist ⚡ | Kailera | 1Q28 | NCT07284979 | |
| Ph1 | GLP-1/GIP | OrsoBio | Oral | 1Q26 | NCT05822544 |
| Ph1 | Cyclooxygenase inhibitor ⚡ | Pfizer | 1Q27 | NCT07508241 | |
| Ph1 | GLP1R ⚡ | RANI | ⏰ 4Q26 | NCT06891287 | |
| Ph1 | 🇨🇳 Glucagon-like peptide 1 receptor agonist ⚡ | Shanghai World Leader | Nasal | ⏰ 3Q26 | NCT07465965 |
| Ph2 | GLP1R ⚡ | Sun Pharmaceutical Indust… | 2Q27 | NCT07282743 | |
| Ph2 | GLP-1 receptor agonist ⚡ | Veru | 4Q27 | NCT07446998 | |
| Ph1 | GLP-1 receptor agonist ⚡ | Vivani Medical | SC | ⏰ 3Q26 | NCT07430059 |
Unclassified programs (165) — mechanism not captured yet
| Phase | Mechanism | Company | Modality | Readout | Trial |
|---|---|---|---|---|---|
| Ph3 | KAI-9531, Placebounclassified | Kailera | NCT07284901 | ||
| Ph3 | Mirikizumab, Mirikizumab, Tirzepatideunclassified | Eli Lilly and Company | NCT06937086 | ||
| Ph3 | Mirikizumab, Mirikizumab, Tirzepatideunclassified | Eli Lilly and Company | NCT06937099 | ||
| Ph3 | KAI-9531, Placebounclassified | Kailera | NCT07284875 | ||
| Ph3 | Cagrilintide, Semaglutide, Placebo cagrilintideunclassified | Novo Nordisk A/S | NCT05567796 | ||
| Ph3 | A Study to Test the Effect of Survodutide (BI 456906) on Cardio…unclassified | Boehringer Ingelheim | NCT06077864 | ||
| Ph3 | A Clinical Study to Evaluate the Effects of Enicepatide (RO7795…unclassified | Hoffmann-La Roche | NCT07351045 | ||
| Ph3 | A Clinical Study to Evaluate the Effects of Enicepatide (RO7795…unclassified | Hoffmann-La Roche | NCT07351058 | ||
| Ph3 | MET097, Placebounclassified | Pfizer | NCT07311850 | ||
| Ph3 | PF-08653944unclassified | Pfizer | NCT07400653 | ||
| Ph3 | XW003 injection, placebo with matching volumeunclassified | Hangzhou Sciwind Bioscien… | NCT07387094 | ||
| Ph3 | HRS-7535, Placebounclassified | Shandong Suncadia Medicin… | NCT07528027 | ||
| Ph3 | XW003 injection, placebo with matching volumeunclassified | Hangzhou Sciwind Bioscien… | NCT07434050 | ||
| Ph3 | Retatrutide, Tirzepatideunclassified | Eli Lilly and Company | NCT06662383 | ||
| Ph3 | GZR18 injection, Placebounclassified | Gan & Lee Pharmaceuticals. | NCT07501832 | ||
| Ph3 | VCT220, Placebounclassified | Vincentage Pharma Co., Ltd | NCT06939296 | ||
| Ph3 | Placebo, GZR18 injectionunclassified | Gan & Lee Pharmaceuticals. | NCT07493057 | ||
| Ph3 | GZR18 injectionunclassified | Gan & Lee Pharmaceuticals. | NCT07292441 | ||
| Ph3 | Mibavademabunclassified | Regeneron Pharmaceuticals | NCT07220772 | ||
| Ph3 | HRS9531, Placebounclassified | Fujian Shengdi Pharmaceut… | NCT06994650 | ||
| Ph3 | Cagrilintide, Semaglutide, Placebo cagrilintideunclassified | Novo Nordisk A/S | NCT06780449 | ||
| Ph3 | MDR-001, Placebounclassified | MindRank AI Ltd | NCT07274137 | ||
| Ph3 | HDM1005 1, HDM1005 2, Placebounclassified | Hangzhou Zhongmei Huadong… | NCT07279194 | ||
| Ph3 | HRS9531, HRS9531placebounclassified | Fujian Shengdi Pharmaceut… | NCT06974851 | ||
| Ph3 | IN-B00009, Placebounclassified | HK inno.N Corporation | NCT07192263 | ||
| Ph3 | RAY1225, Placebounclassified | Guangdong Raynovent Biote… | NCT06893016 | ||
| Ph3 | HRS-7535 Tablets, HRS-7535 Placebo Tabletsunclassified | Shandong Suncadia Medicin… | NCT06904105 | ||
| Ph3 | HM11260C, Placebounclassified | Hanmi Pharmaceutical Comp… | NCT06174779 | ||
| Ph3 | HDM1002 200mg, oral, once daily, 52 weeks, HDM1002 400mg, oral,…unclassified | Hangzhou Zhongmei Huadong… | NCT06885021 | ||
| Ph3 | 5 mg BGM0504 injection, 10 mg BGM0504 injection administered su…unclassified | BrightGene New Bio-Medica… | NCT06704581 | ||
| Ph3 | PF-08653944unclassified | Pfizer | NCT07595549 | ||
| Ph3 | UBT251 Injection 4.0 mg, UBT251 Injection 6.0 mg, UBT251 Inject…unclassified | The United Bio-Technology… | NCT07648225 | ||
| Ph3 | HRS9531 Tablet, HRS9531 Tablet Placebounclassified | Fujian Shengdi Pharmaceut… | NCT07670884 | ||
| Ph3 | A Study to Evaluate the Effects of Enicepatide in Participants …unclassified | Hoffmann-La Roche | NCT07670416 | ||
| Ph3 | Zenagamtide, Placebo ( matched to Zenagamtide)unclassified | Novo Nordisk A/S | NCT07668401 | ||
| Ph2 | KAI-7535, Placebounclassified | Kailera | NCT07497880 | ||
| Ph1+Ph2 | AZD9550, placebo, AZD9550 and AZD6234unclassified | AstraZeneca | NCT06151964 | ||
| Ph2 | PF-08653945, PF-08653944, Placebounclassified | Pfizer | NCT07575932 | ||
| Ph2 | ERX1000unclassified | ERX Pharmaceuticals | NCT07570758 | ||
| Ph2 | NNC0662-0419, Placebounclassified | Novo Nordisk A/S | NCT07184632 | ||
| Ph2 | RO7795081, Placebounclassified | Hoffmann-La Roche | NCT07081958 | ||
| Ph2 | MET097, Placebounclassified | Pfizer | NCT06973720 | ||
| Ph2 | Investigation of the Efficacy of a Probiotic Mixture in Moderat…unclassified | AB Biotics, SA | NCT07193927 | ||
| Ph1+Ph2 | SRSD384 injection, Placebounclassified | Sirius Therapeutics Co., … | NCT07557355 | ||
| Ph1+Ph2 | ALN-CIDEB, Placebounclassified | Regeneron Pharmaceuticals | NCT06836609 | ||
| Ph2 | UBT251, Placebounclassified | Novo Nordisk A/S | NCT07395687 | ||
| Ph2 | AZD6234, Placebo, AZD9550unclassified | AstraZeneca | NCT07017179 | ||
| Ph2 | Ribupatide, Placebounclassified | Kailera | NCT07458269 | ||
| Ph2 | Placebo, Enicepatideunclassified | Carmot Therapeutics, Inc. | NCT06628362 | ||
| Ph1+Ph2 | ALN-4324, Placebounclassified | Alnylam Pharmaceuticals | NCT06845202 | ||
| Ph2 | HM15275, Placebo of HM15275unclassified | Hanmi Pharmaceutical Comp… | NCT07205900 | ||
| Ph2 | NT-0796, Placebounclassified | NodThera Limited | NCT07220629 | ||
| Ph2 | NT-0796, Placebounclassified | NodThera Limited | NCT07055516 | ||
| Ph2 | MOTS-c (MDP), Placebounclassified | Hudson Biotech | NCT07505745 | ||
| Ph2 | NA-931, Tirzepatide, Tirzepatideunclassified | Biomed Industries, Inc. | NCT06732245 | ||
| Ph2 | ZT006, Placebo of ZT006, ZT006unclassified | Beijing QL Biopharmaceuti… | NCT07230132 | ||
| Ph2 | Taldefgrobep Alfa, Placebo, Taldefgrobep Alfaunclassified | Biohaven Therapeutics Ltd. | NCT07281495 | ||
| Ph2 | aleniglipron or placebounclassified | Gasherbrum Bio, Inc., a w… | NCT07169942 | ||
| Ph2 | AZD6234, Placebo to matchunclassified | AstraZeneca | NCT06851858 | ||
| Ph2 | (S)-pindolol benzoate, Semaglutide, Placebo to (S)-pindolol ben…unclassified | Actimed Therapeutics Ltd | NCT07101939 | ||
| Ph1+Ph2 | WVE-007unclassified | Wave Life Sciences USA, I… | NCT06842186 | ||
| Ph2 | Bivamelagonunclassified | Rhythm Pharmaceuticals, I… | NCT07156578 | ||
| Ph1+Ph2 | MET233 and MET097, MET097unclassified | Pfizer | NCT06924320 | ||
| Ph2 | IMM01-STEM, IMM01-STEM alternating with placebo (saline)unclassified | Immunis, Inc. | NCT06600581 | ||
| Ph2 | VCT220 Tablet, VCT220 Placebo Tabletunclassified | Vincentage Pharma Co., Ltd | NCT07360275 | ||
| Ph2 | Petrelintideunclassified | Zealand Pharma | NCT06926842 | ||
| Ph2 | HRS-7535 tablet, HRS-7535 tablet placebounclassified | Shandong Suncadia Medicin… | NCT06820099 | ||
| Ph2 | UBT251, UBT251, UBT251unclassified | The United Bio-Technology… | NCT07134335 | ||
| Ph2 | HRS9531, Placebounclassified | Fujian Shengdi Pharmaceut… | NCT06391710 | ||
| Ph2 | HDM1005 injection or placebounclassified | Hangzhou Zhongmei Huadong… | NCT06886126 | ||
| Ph2 | MKP10241, Placebounclassified | Mankind Pharma Limited | NCT07098663 | ||
| Ph2 | Bimagrumab, Tirzepatide, Bimagrumab Placebounclassified | Eli Lilly and Company | NCT06643728 | ||
| Ph2 | APHD-012, APHD-002, APHP-012unclassified | Aphaia Pharma US LLC | NCT07008456 | ||
| Ph2 | THDBH120 injection, Placebo of THDBH120 injectionunclassified | Tonghua Dongbao Pharmaceu… | NCT07036601 | ||
| Ph2 | S1B-509 low dose, Placebo, S1B-509 High Doseunclassified | S1 Biopharma, Inc. | NCT06517797 | ||
| Ph1+Ph2 | Metformin, Val, Cel and Met XR Low, Val, Cel and Met XR Highunclassified | ARKAY Therapeutics | NCT03686657 | ||
| Ph2 | EMP16-02 120 mg orlistat/40 mg acarbose, Alli® 60 mgunclassified | Empros Pharma AB | NCT06993428 | ||
| Ph2 | EXploratory Study on Postprandial Energy Metabolismunclassified | Lallemand Health Solutions | NCT06786052 | ||
| Ph1+Ph2 | HRS-7535 Tablet, Placebounclassified | Shandong Suncadia Medicin… | NCT06621316 | ||
| Ph2 | RAY1225, Placebounclassified | Guangdong Raynovent Biote… | NCT06254261 | ||
| Ph1+Ph2 | MDR-001, palcebounclassified | MindRank AI Ltd | NCT06778850 | ||
| Ph2 | bremelanotide, tirzepatideunclassified | Palatin Technologies, Inc | NCT06565611 | ||
| Ph2 | KBP-336, Placebounclassified | KeyBioscience AG | NCT06833749 | ||
| Ph2 | GZR18, Tirzepatideunclassified | Gan and Lee Pharmaceutica… | NCT06737042 | ||
| Ph2 | APHD-012, APHD-012Punclassified | Aphaia Pharma US LLC | NCT05385978 | ||
| Ph2 | Effects of Synbiotics on Obesityunclassified | Leeuwenhoek Laboratories … | NCT06578143 | ||
| Ph2 | MDR-001, Placebounclassified | MindRank AI Ltd | NCT06606483 | ||
| Ph2 | HRS9531, HRS9531placebounclassified | Fujian Shengdi Pharmaceut… | NCT06595797 | ||
| Ph2 | The Effects of the GOLO for Life® Plan With Release Supplement …unclassified | Golo | NCT05844644 | ||
| Ph2 | Petrelintide, Petrelintide-matching Placebounclassified | Hoffmann-La Roche | NCT07589686 | ||
| Ph2 | BI 3034701, Placebo matching BI 3034701unclassified | Boehringer Ingelheim | NCT07662122 | ||
| Ph2 | BGM0504 tablets, BGM0504 tablets, BGM0504 tabletsunclassified | BrightGene Bio-Medical Te… | NCT07658560 | ||
| Ph2 | Oral BGE-102, Oral Placebo Matching BGE-102unclassified | BioAge Labs, Inc. | NCT07656727 | ||
| Ph1 | ABBV-295, Placebounclassified | AbbVie | NCT07291232 | ||
| Ph1 | Elecoglipron, Atorvastatin, Rosuvastatinunclassified | AstraZeneca | NCT07534592 | ||
| Ph1 | NNC0497-0040, Placebounclassified | Novo Nordisk A/S | NCT07578584 | ||
| Ph1 | HDM1005unclassified | Hangzhou Zhongmei Huadong… | NCT07559240 | ||
| Ph1 | AZD6234 Formulation 1, AZD6234 Formulation 2 (low concentration…unclassified | AstraZeneca | NCT07220954 | ||
| Ph1 | RO7795081, Placebounclassified | Hoffmann-La Roche | NCT07499050 | ||
| Ph1 | Cagrilintide, Semaglutide, Placebo cagrilintideunclassified | Novo Nordisk A/S | NCT07527195 | ||
| Ph1 | NNC0113-5840, Placebounclassified | Novo Nordisk A/S | NCT07566390 | ||
| Ph1 | HM17321, Placebo of HM17321unclassified | Hanmi Pharmaceutical Comp… | NCT07219589 | ||
| Ph1 | HRS9531 injection；Placebo, HRS9531 injection；Placebo, HRS9531 i…unclassified | Fujian Shengdi Pharmaceut… | NCT07559136 | ||
| Ph1 | SYNT101, Placebounclassified | Syntis Bio | NCT07307274 | ||
| Ph1 | MBX 4291, Placebounclassified | MBX Biosciences | NCT07142707 | ||
| Ph1 | HEC-007 injection, Placebo, HEC-007 injectionunclassified | Sunshine Lake Pharma Co.,… | NCT07102251 | ||
| Ph1 | AZD1043unclassified | AstraZeneca | NCT07511205 | ||
| Ph1 | MK-4082, Placebounclassified | Merck Sharp & Dohme LLC | NCT07388667 | ||
| Ph1 | DWRX5003, DWC202502, DWC202503unclassified | Daewoong Pharmaceutical C… | NCT07539415 | ||
| Ph1 | SYH2082 Injection, Placebounclassified | CSPC ZhongQi Pharmaceutic… | NCT07532655 | ||
| Ph1 | ABBV-295, Placebo for ABBV-295unclassified | AbbVie | NCT07514260 | ||
| Ph1 | BI 456906, Semaglutideunclassified | Boehringer Ingelheim | NCT05202353 | ||
| Ph1 | Glucose-dependent Insulinotropic Polypeptide (GIP), Cagrilintid…unclassified | Novo Nordisk A/S | NCT07411560 | ||
| Ph1 | Placebo, RO7204239unclassified | Hoffmann-La Roche | NCT07137585 | ||
| Ph1 | BMF-650unclassified | Biomea Fusion Inc. | NCT07223216 | ||
| Ph1 | DA-1726, Placebo to DA-1726unclassified | NeuroBo Pharmaceuticals I… | NCT06252220 | ||
| Ph1 | CMS-D008, Placebounclassified | Shenzhen Kangzhe Biotechn… | NCT07518589 | ||
| Ph1 | Placebo, IBI3032 tabletsunclassified | Innovent Biologics Techno… | NCT07160400 | ||
| Ph1 | Acetaminophen, Metformin, Warfarinunclassified | Hangzhou Zhongmei Huadong… | NCT07502001 | ||
| Ph1 | CX11 (VCT220)unclassified | Vincentage Pharma Co., Ltd | NCT07349381 | ||
| Ph1 | IBIO-600, Placebounclassified | iBio, Inc. | NCT07487376 | ||
| Ph1 | Dose escalation of SA030, Matching placebo of SA030unclassified | Suzhou Siran Biotechnolog… | NCT07479862 | ||
| Ph1 | CRB-913, Placebounclassified | Corbus Pharmaceuticals In… | NCT07310901 | ||
| Ph1 | NNC0638-0355, Placebo (NNC0638-0355)unclassified | Novo Nordisk A/S | NCT06577766 | ||
| Ph1 | GS-4571, Placebo, Omeprazoleunclassified | Gilead Sciences | NCT06562907 | ||
| Ph1 | A Study in People With Overweight or Obesity to Compare How 2 D…unclassified | Boehringer Ingelheim | NCT07407348 | ||
| Ph1 | INV-347unclassified | Novo Nordisk A/S | NCT07153172 | ||
| Ph1 | NNC6989-0001 A, Placebo (NNC6989-0001 A)unclassified | Novo Nordisk A/S | NCT07437079 | ||
| Ph1 | PF-08653944unclassified | Pfizer | NCT07400679 | ||
| Ph1 | AMG 513, Placebo, AMG 513unclassified | Amgen | NCT06585462 | ||
| Ph1 | ALV-100, Placebounclassified | Alveus Therapeutics, Inc. | NCT07399678 | ||
| Ph1 | ZT003, ZT003, Placebounclassified | Beijing QL Biopharmaceuti… | NCT07184502 | ||
| Ph1 | RAY1225, atorvastatin calcium tablet, Metformin Tabletsunclassified | Guangdong Raynovent Biote… | NCT07362030 | ||
| Ph1 | GZR18 injection A, GZR18 injection Bunclassified | Gan & Lee Pharmaceuticals. | NCT07355738 | ||
| Ph1 | LAE103 injection, LAE102 injection in combined with LAE103 inje…unclassified | Laekna Limited | NCT07230496 | ||
| Ph1 | HUC2-676, HUC2-676-Runclassified | Huons Co., Ltd. | NCT07337174 | ||
| Ph1 | SGB-7342, SGB-7342-Matching placebounclassified | Suzhou Sanegene Bio Inc. | NCT07324850 | ||
| Ph1 | LAE102 intravenous administration, placebo intravenous administ…unclassified | Laekna Limited | NCT06493084 | ||
| Ph1 | Metformin, Empagliflozin, Midazolamunclassified | Hangzhou Zhongmei Huadong… | NCT07331389 | ||
| Ph1 | IBI3032, placebounclassified | Innovent Biologics Techno… | NCT07170319 | ||
| Ph1 | BGM1812, Placebo, BGM1812unclassified | BrightGene Bio-Medical Te… | NCT07294235 | ||
| Ph1 | SHR-2906 Injection, SHR-2906 Injection Placebounclassified | Beijing Suncadia Pharmace… | NCT07280936 | ||
| Ph1 | GZR18 injection,digoxin tablets, rosuvastatin calcium tablets a…unclassified | Gan & Lee Pharmaceuticals. | NCT07128888 | ||
| Ph1 | GZR18 injectionunclassified | Gan & Lee Pharmaceuticals. | NCT07141030 | ||
| Ph1 | BGM0504 tablets, Placebo tabletsunclassified | BrightGene Bio-Medical Te… | NCT07239973 | ||
| Ph1 | MWN109 tablet, Placebounclassified | Shanghai Minwei Biotechno… | NCT06938269 | ||
| Ph1 | HRS-9531 Tabletunclassified | Fujian Shengdi Pharmaceut… | NCT07150962 | ||
| Ph1 | HRS-5817 Injection, HRS-5817 Injection Placebounclassified | Fujian Shengdi Pharmaceut… | NCT06934408 | ||
| Ph1 | BGM1812, Placebo, BGM1812unclassified | BrightGene Bio-Medical Te… | NCT07224399 | ||
| Ph1 | XTL6001, Placebounclassified | Shanghai Xitaili Biomedic… | NCT07205432 | ||
| Ph1 | BGM0504, BGM0504, BGM0504unclassified | BrightGene Bio-Medical Te… | NCT07166081 | ||
| Ph1 | KN069unclassified | Suzhou Alphamab Co., Ltd. | NCT06547775 | ||
| Ph1 | GZR18 injection, GZR18 injection, GZR18 injectionunclassified | Gan & Lee Pharmaceuticals. | NCT07144098 | ||
| Ph1 | BLX-7006, Placebounclassified | Biolexis Therapeutics | NCT07140055 | ||
| Ph1 | BLX-0871, Placebounclassified | Biolexis Therapeutics | NCT07140081 | ||
| Ph1 | HS235unclassified | 35Pharma Inc | NCT07123779 | ||
| Ph1 | MDR-001, Placebounclassified | MindRank AI Ltd | NCT07110766 | ||
| Ph1 | HS-20094 AI pen;, HS-20094 MDV penunclassified | Jiangsu Hansoh Pharmaceut… | NCT07057674 | ||
| Ph1 | Placebo, Subcutaneous single and mutiple doseunclassified | Shanghai Minwei Biotechno… | NCT06859853 | ||
| Ph1 | GZR18 and metforminunclassified | Gan and Lee Pharmaceutica… | NCT06670209 | ||
| Ph1 | Repaglinide, Atorvastatin, Digoxinunclassified | Hangzhou Zhongmei Huadong… | NCT06601517 | ||
| Ph1 | Cagrilintide D, Cagrilintide B and placebo semaglutide Iunclassified | Novo Nordisk A/S | NCT07597018 | ||
| Ph1 | REGN20934, Placebounclassified | Regeneron Pharmaceuticals | NCT07594093 | ||
| Ph1 | ALN-6222, Placebounclassified | Alnylam Pharmaceuticals | NCT07624071 | ||
| Ph1 | CX11, CX11unclassified | Corxel Pharmaceuticals | NCT07652047 |
Drugs in this landscape: Tirzepatide · Semaglutide · Acetaminophen · Semaglutide Injection · semaglutide injection
Sponsor activity
Who is running trials now — green active, blue completed, red failed/terminated.
Sorted by active Active Done Failed
Eli Lilly 48 47 3
Novo Nordisk 43 98 3
Amgen 10 10 1
Hangzhou Zhongmei Huadong Pharmaceutical Co., Ltd. 10 2 0
Roche 9 1 0
Pfizer 8 17 5
Rhythm Pharmaceuticals, Inc. 7 13 0
Innovent Biologics (Suzhou) Co. Ltd. 7 7 0
BrightGene Bio-Medical Technology Co., Ltd. 7 4 0
Gan & Lee Pharmaceuticals. 7 1 0
Fujian Shengdi Pharmaceutical Co., Ltd. 6 5 0
Boehringer Ingelheim 5 18 0
Gasherbrum Bio, Inc., a wholly owned subsidiary of Structure Therapeutics 5 2 0
Kailera 5 1 0
AstraZeneca 4 10 2
How the field has grown
New-trial starts peaked in 2025 (228 registered). The right-hand chart shows median Phase 3 enrollment by start year — the number in parentheses is that year's Phase 3 trial count (262 in total), so single-trial years (and years with no Phase 3 starts) are obvious. Both are by trial start date; the current year is partial.
New trials started by year
2016 73
2017 72
2018 67
2019 53
2020 56
2021 77
2022 81
2023 116
2024 173
2025 228
2026 160
TheraRadar.com
Median Phase 3 enrollment by start year
2016 (15) 66
2017 (13) 120
2018 (16) 160
2019 (12) 171
2020 (5) 384
2021 (23) 207
2022 (25) 100
2023 (33) 445
2024 (27) 307
2025 (48) 450
2026 (45) 600
TheraRadar.com
Full trial pipeline
Every active and completed trial across Phase 1–4, with enrollment analytics. Sortable, filterable, exportable with Pro.
NCT07339423 RECRUITING
AMAZE 1: A Research Study Investigating How Well the Medicine NNC0487-0111 Helps People With Excess Body Weight Lose Weight
Novo Nordisk A/S n=1,150
NCT07284901 RECRUITING
Efficacy and Safety of KAI-9531 Administered Once Weekly in Participants Living With Obesity or Overweight and Diabetes
Kailera n=1,700
NCT06937086 RECRUITING
Mirikizumab Administered at the Same Time as Tirzepatide in Adult Participants With Moderately to Severely Active Ulcerative Colitis and Obesity or Overweight: Phase 3b Study
Eli Lilly and Company n=350
NCT06937099 RECRUITING
Mirikizumab and Tirzepatide Administered in Adult Participants With Moderately to Severely Active Crohn's Disease and Obesity or Overweight
Eli Lilly and Company n=290
NCT06672549 RECRUITING
A Platform Trial for Pediatric Participants With Obesity or Overweight (LY900040)
Eli Lilly and Company n=125
NCT06914895 ACTIVE NOT RECRUITING
A Study of Tirzepatide (LY3298176) Compared With Placebo in Adults With Type 1 Diabetes and Obesity or Overweight
Eli Lilly and Company n=905
NCT06439277 RECRUITING
A Study of Tirzepatide in Adolescents With Obesity and Weight-Related Comorbidities (SURMOUNT-ADOLESCENTS-2)
Eli Lilly and Company n=300
NCT06884293 ACTIVE NOT RECRUITING
A Study Comparing IBI362 vs Semaglutide in Chinese Overweight or Obese Adults With Metabolic Dysfunction-associated Fatty Liver Disease （MAFLD）
Innovent Biologics (Suzhou) Co. Ltd. n=479
NCT07037433 RECRUITING
Evaluating the Impact of Maridebart Cafraglutide on Cardiovascular Outcomes in Participants With Atherosclerotic Cardiovascular Disease and Overweight or Obesity
Amgen n=12,800
NCT07575399 RECRUITING
Efficacy, Safety and Tolerability of Switching From Glucagon-like Peptide-1 Receptor Agonists (GLP-1RA) to Maridebart Cafraglutide in Adults With Obesity or Overweight (MARITIME-SWITCH)
Amgen n=300
NCT07284875 RECRUITING
Efficacy and Safety of KAI-9531 in Participants Living With Obesity or Overweight With Weight-Related Comorbidities Who Do Not Have Diabetes
Kailera n=1,800
NCT07298915 NOT YET RECRUITING
The Effect of Exercise and Tirzepatide on Weight and Health Outcomes (EXER-MED)
University of Virginia n=24
NCT07571109 RECRUITING
AMAZE 4: A Research Study Investigating How Well the Medicine NNC0487-0111 Helps People With Excess Body Weight and Obstructive Sleep Apnoea Treated With Positive Airway Pressure Lose Weight and Improve Sleep Apnoea
Novo Nordisk A/S n=300
NCT07571005 RECRUITING
AMAZE 3: A Research Study Investigating How Well the Medicine NNC0487-0111 Helps People With Excess Body Weight and Obstructive Sleep Apnoea Not Treated With Positive Airway Pressure Lose Weight and Improve Sleep Apnoea
Novo Nordisk A/S n=300
NCT07225686 RECRUITING
Maridebart Cafraglutide Versus Placebo in Adult Participants With Obstructive Sleep Apnea on Positive Airway Pressure Therapy
Amgen n=250
NCT05567796 ACTIVE NOT RECRUITING
A Research Study to See How Well CagriSema Helps People With Excess Body Weight Lose Weight
Novo Nordisk A/S n=3,400
NCT07503210 RECRUITING
AMAZE 12: A Research Study Investigating How Well the Medicine NNC0487-0111 Helps People With Excess Body Weight Maintain Their Weight Loss
Novo Nordisk A/S n=600
NCT07037459 RECRUITING
Maridebart Cafraglutide in Heart Failure With Preserved or Mildly Reduced Ejection Fraction and Obesity
Amgen n=5,056
NCT07567001 NOT YET RECRUITING
A Research Study to Look at How Well NNC0487-0111 Works Compared to Placebo in People With Heart Failure and Obesity
Novo Nordisk A/S n=5,610
NCT07564414 RECRUITING
A Research Study to Look at How Two Different Doses of CagriSema and One Dose of Semaglutide Help People Living With Obesity With or Without Type 2 Diabetes Lose Weight
Novo Nordisk A/S n=2,500
NCT06077864 ACTIVE NOT RECRUITING
A Study to Test the Effect of Survodutide (BI 456906) on Cardiovascular Safety in People With Overweight or Obesity (SYNCHRONIZE™ - CVOT)
Boehringer Ingelheim n=5,531
NCT07284979 RECRUITING
Efficacy and Safety of KAI-9531 Administered Once Weekly Compared With Semaglutide and Placebo in Participants Living With Obesity Who Do Not Have Diabetes
Kailera n=1,200
NCT07481630 RECRUITING
A Research Study Investigating How Well the Medicine NNC0487-0111 Helps People With Excess Body Weight and Knee Osteoarthritis Lose Weight and Reduce Pain
Novo Nordisk A/S n=400
NCT07533175 RECRUITING
AMAZE 2: A Research Study Investigating How Well the Medicine NNC0487-0111 Helps People With Excess Body Weight and Type 2 Diabetes Lose Weight
Novo Nordisk A/S n=630
NCT06993792 ACTIVE NOT RECRUITING
A Master Protocol for Orforglipron (LY3502970) in Participants With Obesity or Overweight With and Without Type 2 Diabetes
Eli Lilly and Company n=1,200
NCT07351045 RECRUITING
A Clinical Study to Evaluate the Effects of Enicepatide (RO7795068) in Participants With Obesity or Overweight Without Type 2 Diabetes
Hoffmann-La Roche n=2,000
NCT07351058 RECRUITING
A Clinical Study to Evaluate the Effects of Enicepatide (RO7795068) in Participants With Obesity or Overweight and Type 2 Diabetes
Hoffmann-La Roche n=1,600
NCT06972459 ACTIVE NOT RECRUITING
A Study of Orforglipron (LY3502970) in Participants With Obesity or Overweight and at Least One Weight-Related Comorbidity
Eli Lilly and Company n=600
NCT05726227 ACTIVE NOT RECRUITING
A Research Study on How Well Semaglutide Helps Children and Teenagers With Excess Body Weight Lose Weight
Novo Nordisk A/S n=210
NCT07220759 ACTIVE NOT RECRUITING
Weight Loss in People Living With Overweight or Obesity and Type 2 Diabetes Following Treatment With Cagrilintide
Novo Nordisk A/S n=330
NCT07311850 RECRUITING
Efficacy and Safety of MET097 Once-Weekly in People With Overweight or Obesity
Pfizer n=3,501
NCT06972472 ACTIVE NOT RECRUITING
A Study of Orforglipron (LY3502970) in Participants With Obesity or Overweight and Type 2 Diabetes
Eli Lilly and Company n=600
NCT07357415 ACTIVE NOT RECRUITING
A Study of Retatrutide (LY3437943) in Participants Without Type 2 Diabetes Who Have Obesity or Overweight
Eli Lilly and Company n=600
NCT07321886 RECRUITING
A Study of Eloralintide (LY3841136) in Participants With Obesity, or Overweight Without Type 2 Diabetes
Eli Lilly and Company n=1,980
NCT07446439 RECRUITING
A Study to Evaluate Tradipitant on Treating Nausea and Vomiting Induced by GLP-1R Agonist Use
Vanda Pharmaceuticals n=280
NCT07400653 RECRUITING
A Study to Learn About the Study Medicine (PF-08653944) in People With Obesity or Overweight and Type 2 Diabetes (T2D)
Pfizer n=999
NCT07392190 RECRUITING
A Study of Eloralintide (LY3841136) in Participants With Persistent Obesity Who Are Treated With a Weekly Incretin
Eli Lilly and Company n=900
NCT07282600 RECRUITING
A Study of Eloralintide (LY3841136) in Participants With Obesity or Overweight, and Type 2 Diabetes
Eli Lilly and Company n=1,035
NCT07353931 RECRUITING
Efficacy and Safety of Eloralintide (LY3841136) in Participants With Osteoarthritis Knee Pain and Obesity or Overweight
Eli Lilly and Company n=900
NCT06948435 ACTIVE NOT RECRUITING
A Master Protocol Study of Orforglipron (LY3502970) in Participants With Hypertension and Obesity or Overweight (ATTAIN-Hypertension) GZL1
Eli Lilly and Company n=487
NCT07369011 RECRUITING
A Study of Eloralintide (LY3841136) in Participants With Obstructive Sleep Apnea and Obesity or Overweight
Eli Lilly and Company n=800
NCT07035093 RECRUITING
A Study of Retatrutide (LY3437943) in Participants Who Have Obesity or Overweight and Chronic Low Back Pain
Eli Lilly and Company n=586
NCT07232719 ACTIVE NOT RECRUITING
A Study of Retatrutide (LY3437943) in Participants With Obesity or Overweight
Eli Lilly and Company n=250
NCT07387094 RECRUITING
A Study of XW003 in Obese Participants With Obstructive Sleep Apnea But Not Receive Positive Airway Pressure Therapy
Hangzhou Sciwind Biosciences Co., Ltd. n=140
NCT07434050 RECRUITING
A Study of XW003 in Obese Participants With Obstructive Sleep Apnea Receiving Positive Airway Pressure Therapy
Hangzhou Sciwind Biosciences Co., Ltd. n=140
NCT06662383 ACTIVE NOT RECRUITING
A Study of Retatrutide (LY3437943) Compared to Tirzepatide (LY3298176) in Adults Who Have Obesity
Eli Lilly and Company n=800
NCT05929079 ACTIVE NOT RECRUITING
A Study of Retatrutide (LY3437943) in Participants With Type 2 Diabetes Mellitus Who Have Obesity or Overweight
Eli Lilly and Company n=1,000
NCT04971720 RECRUITING
PRECISION-BP: Precision Chronopharamacotherapy Targeting NP-RAAS-BP Rhythm Axis
University of Alabama at Birmingham n=160
NCT07220642 ACTIVE NOT RECRUITING
Weight Loss in People Living With Overweight or Obesity Following Treatment With Cagrilintide
Novo Nordisk A/S n=300
NCT07509307 RECRUITING
AMAZE 6: A Research Study Investigating How Well the Medicine NNC0487-0111 Helps People With Excess Body Weight and Knee Osteoarthritis Lose Weight and Reduce Pain
Novo Nordisk A/S n=400
NCT07253285 RECRUITING
A Research Study on How Well Cagrilintide and CagriSema Work in Children and Adolescents With Excess Body Weight
Novo Nordisk A/S n=460
NCT06939296 ACTIVE NOT RECRUITING
A Research Study of VCT220 in Adult Chinese Participants With Obesity
Vincentage Pharma Co., Ltd n=840
NCT04599478 ACTIVE NOT RECRUITING
Pharmacological and Behavioral Treatment After Bariatric Surgery: Acute (Stage 1)
Yale University n=160
NCT07481747 RECRUITING
Efficacy and Safety of Tirzepatide Once Weekly Versus Placebo in Participants Who Are Either Obese or Overweight With Weight-Related Comorbidities (SURMOUNT-1)
Hudson Biotech n=2,539
NCT05653258 RECRUITING
Single Nuclei RNA-seq to Map Adipose Cellular Populations and Senescent Cells in Older Subjects
Cedars-Sinai Medical Center n=160
NCT06934655 NOT YET RECRUITING
Early Re-Initiation of Semaglutide Post Sleeve Gastrectomy in Youth
Children's Hospital Los Angeles n=150
NCT07469800 RECRUITING
Efficacy and Safety of IBI362 in Hypertensive Patients With Overweight/Obesity
Innovent Biologics (Suzhou) Co. Ltd. n=336
NCT07400107 NOT YET RECRUITING
AMAZE 8: A Research Study Investigating How Well the Medicine NNC0487-0111 Compared to Semaglutide Helps People With Excess Body Weight and Type 2 Diabetes Lose Weight
Novo Nordisk A/S n=1,000
NCT07292441 RECRUITING
Extension Study of the Phase 3 Clinical Study of GZR18 Injection for Weight Loss
Gan & Lee Pharmaceuticals. n=500
NCT07220772 RECRUITING
A Study Evaluating Mibavademab Treatment of Obesity Due to Leptin (LEP) Gene Mutations in Children, Adolescents and Adults
Regeneron Pharmaceuticals n=4
NCT06162715 ENROLLING BY INVITATION
GLP-1 Receptor Agonists Post-Bariatric Surgery (GRABS) Pilot Trial
Vanderbilt University Medical Center n=30
NCT06859268 ACTIVE NOT RECRUITING
A Study of Retatrutide (LY3437943) in the Maintenance of Weight Reduction in Individuals With Obesity
Eli Lilly and Company n=643
NCT07285902 ACTIVE NOT RECRUITING
A Study Comparing the Efficacy and Safety of HRS9531 Injection With Semaglutide Injection in Subjects With Obesity
Fujian Shengdi Pharmaceutical Co., Ltd. n=572
NCT07357766 NOT YET RECRUITING
A Research Study to Compare Different Versions of Injectable CagriSema and Placebo in People With Excess Body Weight
Novo Nordisk A/S n=1,400
NCT06987383 NOT YET RECRUITING
Vibegron for ENergy Thinking and Resilience in Aging
Wake Forest University Health Sciences n=40
NCT06962280 ACTIVE NOT RECRUITING
A Long-Term Study of Tirzepatide (LY3298176) in Adults With Type 1 Diabetes and Obesity or Overweight
Eli Lilly and Company n=465
NCT06760546 RECRUITING
A Trial of Setmelanotide in Patients With Congenital Hypothalamic Obesity (Sub-study of NCT05774756)
Rhythm Pharmaceuticals, Inc. n=39
NCT07294950 RECRUITING
Impact of Semaglutide Withdrawal on Cardiometabolic Profile and Physiology of Energy Balance: Recovery Effects After Semaglutide Termination
Mount Sinai Hospital, Canada n=98
NCT05093634 ACTIVE NOT RECRUITING
EMANATE: A Study of Setmelanotide in Patients With Specific Gene Variants in the MC4R Pathway
Rhythm Pharmaceuticals, Inc. n=296
NCT04599504 ACTIVE NOT RECRUITING
Pharmacological and Behavioral Treatment After Bariatric Surgery: Medication Change for Non-Responders (Stage 2b)
Yale University n=60
NCT06921486 ACTIVE NOT RECRUITING
The Efficacy and Safety of Efsubaglutide Alfa Injection in Overweight and Obese Subjects (ENLIGHT)
Shanghai Yinnuo Pharmaceutical Technology Co., Ltd. n=1,003
NCT04605081 ACTIVE NOT RECRUITING
Pharmacological and Behavioral Treatments After Bariatric Surgery: Maintenance Treatment (Stage 2a)
Yale University n=100
NCT06994650 RECRUITING
A Multicenter, Randomized, Double-blind, Placebo-controlled Phase III Clinical Study to Evaluate the Efficacy and Safety of HRS9531 Injection in Subjects With Obstructive Sleep Apnea (OSA) and Obesity Who Are on Positive Airway Pressure Ventilation (PAP) Therapy
Fujian Shengdi Pharmaceutical Co., Ltd. n=140
NCT06780449 ACTIVE NOT RECRUITING
A Research Study to Look Into the Long-term Effect on Weight Loss of CagriSema in People With Obesity
Novo Nordisk A/S n=400
NCT05556512 ACTIVE NOT RECRUITING
A Study of Tirzepatide (LY3298176) on the Reduction on Morbidity and Mortality in Adults With Obesity
Eli Lilly and Company n=15,374
NCT07332273 RECRUITING
Levothyroxine as Adjuvant to a Hypocaloric Diet for the Treatment of Obesity.
Fundación Pública Andaluza para la Investigación de Málaga en Biomedicina y Salud n=286
NCT07255209 RECRUITING
A Study of IBI362 in Chinese Adolescents With Obesity or Overweight
Innovent Biologics (Suzhou) Co. Ltd. n=180
NCT04520490 ACTIVE NOT RECRUITING
Brain Activation and Satiety in Children 2
Seattle Children's Hospital n=63
NCT07230119 NOT YET RECRUITING
A Study of Zovaglutide in Subjects With Overweight or Obesity (HORIZON-1)
Beijing QL Biopharmaceutical Co.,Ltd n=744
NCT07274137 NOT YET RECRUITING
A Phase III Study to Evaluate the Efficacy and Safety of MDR-001 in Adult Participants With Overweight or Obesity (MOBILE）
MindRank AI Ltd n=738
NCT07297290 RECRUITING
Effect of Metformin Use on Weight Loss in Obese, Non-diabetic People (MOWRI)
University Of Nigeria Teaching Hospital n=220
NCT06987695 ACTIVE NOT RECRUITING
Efficacy and Safety of Maridebart Cafraglutide in Adult Participants in Japan Who Have Obesity Disease
Amgen n=279
NCT07011667 ACTIVE NOT RECRUITING
A Research Study to Look at How Well CagriSema Helps People Living With Obesity Lose Weight and Maintain Weight Loss in the Long-term
Novo Nordisk A/S n=609
NCT07279194 RECRUITING
Efficacy and Safety of HDM1005 in Chinese Obesity or Overweight Patients Without Diabetes
Hangzhou Zhongmei Huadong Pharmaceutical Co., Ltd. n=825
NCT04775082 ACTIVE NOT RECRUITING
SCALE KIDS: Research Study to Look at How Well a New Medicine is at Lowering Weight in Children With Obesity
Novo Nordisk A/S n=78
NCT07150975 RECRUITING
Phase III Clinical Study Comparing the Efficacy and Safety of GZR18 Injection and Semaglutide (Wegovy®) in Adult Obese or Overweight Subjects
Gan & Lee Pharmaceuticals. n=420
NCT06728124 ACTIVE NOT RECRUITING
A Phase III Clinical Study to Evaluate the Efficacy and Safety of GZR18 Injection in Adult Obese/Overweight Subjects
Gan & Lee Pharmaceuticals. n=630
NCT06974851 RECRUITING
A Phase III Study Evaluating the Efficacy and Safety of HRS9531 Injection in Subjects With Obstructive Sleep Apnea (OSA) and Obesity
Fujian Shengdi Pharmaceutical Co., Ltd. n=140
NCT04578652 RECRUITING
Fiber and Metformin Combination Therapy in Adolescents With Severe Obesity and Insulin Resistance
University of Alberta n=90
NCT06499857 RECRUITING
Semaglutide for Metabolic Intervention and Adipose Loss to Treat Atrial Fibrillation
University of Chicago n=200
NCT05869903 ACTIVE NOT RECRUITING
A Study of Orforglipron (LY3502970) in Adult Participants With Obesity or Overweight With Weight-Related Comorbidities
Eli Lilly and Company n=3,127
NCT06672939 RECRUITING
A Study of Orforglipron (LY3502970) in Adolescent Participants With Obesity, or Overweight With Related Comorbidities
Eli Lilly and Company n=150
NCT06858839 ACTIVE NOT RECRUITING
Evaluation of Maridebart Cafraglutide in Adult Participants Without Type 2 Diabetes Mellitus Who Have Obesity or Are Overweight
Amgen n=3,853
NCT05887271 RECRUITING
A Randomised, Controlled Trial of a Low-energy Diet for Improving Functional Status in Heart Failure With PRESERVED Ejection Fraction Preserved Ejection Fraction
University of Leicester n=63
NCT06649045 ACTIVE NOT RECRUITING
A Master Protocol for Orforglipron in Participants With Obstructive Sleep Apnea and Obesity or Overweight
Eli Lilly and Company n=600
NCT07192263 NOT YET RECRUITING
Study to Evaluate the Efficacy and Safety of IN-B00009 Injection in Adults With Obesity or Overweight Without Diabetes Mellitus
HK inno.N Corporation n=300
NCT06596135 ENROLLING BY INVITATION
Open-Label Extension Study of Setmelanotide
Rhythm Pharmaceuticals, Inc. n=30
NCT05935826 RECRUITING
Effect of Amino Acids on Hepatic Fat Content in Adolescents (AMINOS Study)
University of Colorado, Denver n=55
NCT07075146 RECRUITING
DOR/TDF/3TC COmpared With BIC/FTC/TAF in ART-Naïve People Living With HIV and Overweight or Obesity
José Antonio Mata Marín n=306
NCT06379113 RECRUITING
GnRHa + Letrozole in Obese Progestin-insensitive Endometrial Cancer Patients
Xiaojun Chen n=29
NCT05316493 RECRUITING
Weight Management Plus LNG-IUS/Megestrol Acetate in Endometrial Atypical Hyperplasia
Xiaojun Chen n=172
NCT06390904 ACTIVE NOT RECRUITING
GnRHa + Letrozole in Obese Progestin-insensitive Endometrial Atypical Hyperplasia Patients
Xiaojun Chen n=29
NCT06909006 NOT YET RECRUITING
Semaglutide Treatment in Type 1 Diabetes
Nordsjaellands Hospital n=122
NCT05882045 ACTIVE NOT RECRUITING
A Study of Retatrutide (LY3437943) in Participants With Obesity and Cardiovascular Disease
Eli Lilly and Company n=1,946
NCT06893016 RECRUITING
Evaluation of RAY1225 in Adult Participants Who Have Obesity or Are Overweight
Guangdong Raynovent Biotech Co., Ltd n=640
NCT05774756 ACTIVE NOT RECRUITING
A Trial of Setmelanotide in Acquired Hypothalamic Obesity
Rhythm Pharmaceuticals, Inc. n=143
NCT06931028 RECRUITING
A Study of IBI362 in Chinese Subjects With Obstructive Sleep Apnea and BMI≥28 kg/m2
Innovent Biologics (Suzhou) Co. Ltd. n=260
NCT07036172 RECRUITING
Efficacy and Safety of Semaglutide Injection Vs WEGOVY® in Chinese Obese Patients
Hangzhou Zhongmei Huadong Pharmaceutical Co., Ltd. n=460
NCT06075667 ACTIVE NOT RECRUITING
A Study of Tirzepatide (LY3298176) Once Weekly in Adolescent Participants Who Have Obesity or Overweight With Weight-Related Comorbidities
Eli Lilly and Company n=150
NCT06904105 ACTIVE NOT RECRUITING
A Trial of HRS-7535 Tablets in Subjects With Overweight or Obesity
Shandong Suncadia Medicine Co., Ltd. n=556
NCT05157698 ACTIVE NOT RECRUITING
Pharmacological and Behavioral Treatment After Bariatric Surgery
Yale University n=84
NCT07021937 NOT YET RECRUITING
Brain Plasticity and GLP-1 Receptor Agonist Treatment for Obesity
University of Colorado, Denver n=120
NCT03516968 RECRUITING
Monthly Boluses Versus Daily Doses for Correcting Blood Vitamin D Deficit in Obese Children and Adolescents
Hospices Civils de Lyon n=68
NCT06174779 ACTIVE NOT RECRUITING
A Study to Evaluate Efficacy and Safety of HM11260C in Adult Obesity Patients Without Diabetes Mellitus
Hanmi Pharmaceutical Company Limited n=420
NCT05816798 RECRUITING
Photobiomodulation in Chronic Knee Pain in Patients Who Are in PreRehabilitation for Bariatric Surgery
University of Nove de Julho n=62
NCT06937060 RECRUITING
Effect of Semaglutide in Patients With Psoriasis and Obesity
The University of Hong Kong n=14
NCT06918405 ACTIVE NOT RECRUITING
Efficacy and Safety of Tirzepatide for Weight Management
Chittagong Medical College n=440
NCT06896981 RECRUITING
Semaglutide in Women With Polycystic Ovary Syndrome and Obesity
Bangabandhu Sheikh Mujib Medical University, Dhaka, Bangladesh n=30
NCT06885021 NOT YET RECRUITING
Evaluate the Safety and Efficacy of HDM1002 Tablets in Chinese Overweight and Obese Adults
Hangzhou Zhongmei Huadong Pharmaceutical Co., Ltd. n=780
NCT06363747 ACTIVE NOT RECRUITING
The Medically Reproducing Bariatric Surgery (MRB) II Study
Durham VA Medical Center n=50
NCT06738979 NOT YET RECRUITING
A Clinical Study Comparing Semaglutide Injection and Wegovy® for Weight Management in Obese Subjects
Chia Tai Tianqing Pharmaceutical Group Co., Ltd. n=408
NCT05073835 ACTIVE NOT RECRUITING
Semaglutide 2.4 mg in Patients With Poor Weight-loss
University College, London n=70
NCT06704581 RECRUITING
A Study of BGM0504 Injection in Participants with Obesity or Overweight
BrightGene New Bio-Medical Technology(Wuxi) Co.Ltd. n=620
NCT06633783 NOT YET RECRUITING
A Phase III Study Comparing the Weight Loss Effects of Semaglutide Injection and Wegovy®
Hangzhou Jiuyuan Gene Engineering Co. Ltd., n=370
NCT06616961 NOT YET RECRUITING
Efficacy and Safety of Semaglutide for Weight Loss in Overweight or Obese Adults in Bangladesh With or Without Type 2 Diabetes Mellitus
Popular Medical College Hospital n=480
NCT06164873 ACTIVE NOT RECRUITING
A Study of IBI362 9 mg in Chinese Adults With Obesity
Innovent Biologics (Suzhou) Co. Ltd. n=462
NCT06423599 RECRUITING
Effect of Weight Loss on Physical and Cardiac Performance in People With Obesity and Heart Failure
Jens D Hove, MD,PHD n=100
NCT07595549 RECRUITING
A Study to Learn About the Study Medicine Called Berobenatide (PF-08653944) in People With Overweight or Obesity
Pfizer n=954
NCT07629544 NOT YET RECRUITING
A Study of DA-302168S in Participants With Overweight/Obesity
Chendu DIAO Pharmaceutical Group CO., LTD. n=840
NCT07622810 NOT YET RECRUITING
BALANCE-OBS: Bofanglutide (GZR18) Versus Semaglutide in Latin American Adults With Overweight or Obesity
Carnot Laboratories n=352
NCT07622290 NOT YET RECRUITING
Metformin Treatment for Children With Obesity-associated Asthma
Prof Ibrahim Janahi n=182
NCT07648225 NOT YET RECRUITING
UBT251 Injection Phase Ⅲ Study (Overweight or Obesity)
The United Bio-Technology (Hengqin) Co., Ltd. n=600
NCT07670416 RECRUITING
A Study to Evaluate the Effects of Enicepatide in Participants With Obesity or Overweight, With or Without Type 2 Diabetes
Hoffmann-La Roche n=300
NCT07668414 NOT YET RECRUITING
A Research Study Investigating How Well the Medicine Zenagamtide Helps People With Excess Body Weight Lose Weight Compared to Semaglutide
Novo Nordisk A/S n=650
NCT07668401 NOT YET RECRUITING
AMAZE 13: A Research Study Investigating How Well the Medicine Zenagamtide Helps People in Asia With Excess Body Weight Lose Weight
Novo Nordisk A/S n=400
NCT07654361 NOT YET RECRUITING
Efficacy and Safety of Aleniglipron in Participants With Obesity or Overweight With a Weight-Related Comorbidity (ACCOMPLISH-1)
Gasherbrum Bio, Inc., a wholly owned subsidiary of Structure Therapeutics n=3,600
NCT07654374 NOT YET RECRUITING
A Study of Aleniglipron in Adults With Obesity or Overweight and Type 2 Diabetes Mellitus (ACCOMPLISH-2)
Gasherbrum Bio, Inc., a wholly owned subsidiary of Structure Therapeutics n=1,100
NCT06588296 COMPLETED
Ixekizumab Concomitantly Administered With Tirzepatide in Adults With Psoriatic Arthritis and Obesity or Overweight
Eli Lilly and Company n=279
NCT02860923 COMPLETED
Efficacy and Safety of Exenatide in the Treatment of Hypothalamic Obesity After Craniopharyngioma Therapy
University Hospital, Bordeaux n=42
NCT05514535 COMPLETED
A Research Study to Look Into How Semaglutide, Together With a Lower Dose of Insulin Glargine, Compares to a Higher Dose of Insulin Glargine Alone in People With Type 2 Diabetes (SUSTAIN OPTIMIZE)
Novo Nordisk A/S n=573
NCT02042664 COMPLETED
Effect of GLP-1 Receptor (GLP-1R) Agonists on Cardiac Function and on Epicardial Adipose Tissue (EAT) Volume and on Myocardial TG Content in Obese Diabetics
Assistance Publique Hopitaux De Marseille n=44
NCT05035095 COMPLETED
Research Study to Investigate How Well Semaglutide Tablets Taken Once Daily Work in People Who Are Overweight or Living With Obesity (OASIS 1)
Novo Nordisk A/S n=667
NCT06388187 COMPLETED
A Research Study to See How Well Different Doses of CagriSema Help People With Excess Body Weight Lose Weight
Novo Nordisk A/S n=300
NCT06309992 COMPLETED
A Study to Test Whether Survodutide Helps People Living With Obesity or Overweight and With a Confirmed or Presumed Liver Disease Called Non-alcoholic Steatohepatitis (NASH) to Reduce Liver Fat and to Lose Weight (SYNCHRONIZE-MASLD)
Boehringer Ingelheim n=218
NCT06214741 COMPLETED
A Study to Test Whether Survodutide (BI 456906) Helps Chinese People Living With Overweight or Obesity to Lose Weight
Boehringer Ingelheim n=307
NCT06176365 COMPLETED
A Study to Test Whether Survodutide Helps Japanese People Living With Obesity Disease
Boehringer Ingelheim n=274
NCT01812694 COMPLETED
Lifestyle Interventions for Expectant Mothers (LIFE-Moms Phoenix) - Phoenix
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) n=123
NCT05649137 COMPLETED
A Research Study to See How Semaglutide Helps People With Excess Weight and Type 2 Diabetes Lose Weight
Novo Nordisk A/S n=512
NCT06066528 COMPLETED
A Study to Test Whether Survodutide (BI 456906) Helps People Living With Overweight or Obesity Who Also Have Diabetes to Lose Weight
Boehringer Ingelheim n=755
NCT05646706 COMPLETED
A Research Study to See How Semaglutide Helps People With Excess Weight, Lose Weight (STEP UP)
Novo Nordisk A/S n=1,407
NCT05803421 COMPLETED
A Study of Daily Oral Orforglipron (LY3502970) Compared With Insulin Glargine in Participants With Type 2 Diabetes and Obesity or Overweight at Increased Cardiovascular Risk
Eli Lilly and Company n=2,749
NCT06619015 WITHDRAWN
Tailoring Obesity Treatment Trial
Esbjerg Hospital - University Hospital of Southern Denmark
NCT06047548 COMPLETED
A Study of LY3298176 (Tirzepatide) For the Maintenance of Body Weight Reduction in Participants Who Have Obesity or Overweight With Weight-Related Comorbidities
Eli Lilly and Company n=441
NCT05172999 COMPLETED
Loxenatide Plus LNG-IUS in Endometrial Atypical Hyperplasia
Fudan University n=30
NCT06066515 COMPLETED
A Study to Test Whether Survodutide (BI 456906) Helps People Living With Overweight or Obesity Who do Not Have Diabetes to Lose Weight
Boehringer Ingelheim n=726
NCT05564117 COMPLETED
Research Study Looking at How Well Semaglutide Tablets Taken Once Daily Work in People Who Have a Body Weight Above the Healthy Range
Novo Nordisk A/S n=307
NCT06184568 COMPLETED
A Study Comparing IBI362 vs Semaglutide in Chinese Adults With Early Type 2 Diabetes and Obesity
Innovent Biologics (Suzhou) Co. Ltd. n=349
NCT06131437 COMPLETED
A Research Study to See How Well CagriSema Compared to Tirzepatide Helps People With Obesity Lose Weight
Novo Nordisk A/S n=809
NCT04251156 COMPLETED
Research Study of How Well Semaglutide Works in People Living With Overweight or Obesity.
Novo Nordisk A/S n=375
NCT05040971 COMPLETED
Research Study Looking at How Well Semaglutide Works in People Living With Obesity and Prediabetes
Novo Nordisk A/S n=207
NCT05394519 COMPLETED
A Research Study to See How Well CagriSema Helps People With Type 2 Diabetes and Excess Body Weight Lose Weight
Novo Nordisk A/S n=1,200
NCT05813925 COMPLETED
A Research Study to See How Well CagriSema Helps People in East Asia With Excess Body Weight Lose Weight
Novo Nordisk A/S n=331
NCT05890976 COMPLETED
Research Study Looking at How Well Semaglutide Tablets Taken Once Daily Work in Chinese Adults Who Are Above a Healthy Weight Range (OASIS 3)
Novo Nordisk A/S n=200
NCT05931367 COMPLETED
A Study of Retatrutide (LY3437943) Once Weekly in Participants Who Have Obesity or Overweight and Osteoarthritis of the Knee
Eli Lilly and Company n=445
NCT06588283 COMPLETED
Ixekizumab Concomitantly Administered With Tirzepatide in Adults With Moderate-to-Severe Plaque Psoriasis and Obesity or Overweight
Eli Lilly and Company n=281
NCT06041217 COMPLETED
A Research Study to See How Well Semaglutide Helps People Who Have a Body Weight Above the Healthy Weight Range
Novo Nordisk A/S n=242
NCT05996848 COMPLETED
A Research Study to See How Well CagriSema Helps People in China With Excess Body Weight Lose Weight
Novo Nordisk A/S n=300
NCT03946111 COMPLETED
Cognitive-Behavioral and Pharmacologic (LDX) Treatment of Binge-Eating Disorder and Obesity: Medication Change for Non-Responders
Yale University n=3
NCT04221750 COMPLETED
Diet and Exercise Plus Metformin to Treat Frailty in Obese Seniors
VA Office of Research and Development n=114
NCT04998136 COMPLETED
Research Study Investigating How Well Semaglutide Works in People From Thailand and South Korea Living With Obesity
Novo Nordisk A/S n=150
NCT06584916 COMPLETED
A Study of Orforglipron for the Maintenance of Body Weight Reduction in Participants Who Have Obesity or Overweight With Weight-Related Comorbidities (ATTAIN-MAINTAIN)
Eli Lilly and Company n=376
NCT02525016 COMPLETED
Safety Profile of IntRAvenous Lidocaine Use in Coelioscopic Bariatric Surgery
Hospices Civils de Lyon n=50
NCT05209984 WITHDRAWN
A Phase 3, Double-blind/Double-dummy, Safety/Efficacy/Superiority of Sibutramine/Topiramate XR in Adults With Overweight
Eurofarma Laboratorios S.A.
NCT03926052 COMPLETED
Cognitive-Behavioral and Pharmacologic (LDX) Treatment of Binge-Eating Disorder and Obesity: Maintenance Treatment
Yale University n=61
NCT04102189 COMPLETED
A Research Study on How Well Semaglutide Works in Adolescents With Overweight or Obesity
Novo Nordisk A/S n=201
NCT04788511 COMPLETED
Research Study to Investigate How Well Semaglutide Works in People Living With Heart Failure and Obesity
Novo Nordisk A/S n=529
NCT05822830 COMPLETED
A Study of Tirzepatide (LY3298176) in Participants With Obesity or Overweight With Weight Related Comorbidities
Eli Lilly and Company n=751
NCT03919929 COMPLETED
Treating PCOS With Semaglutide vs Active Lifestyle Intervention
University of Colorado, Denver n=60
NCT05064735 COMPLETED
Research Study Looking at How Well Semaglutide Works in People Suffering From Obesity and Knee Osteoarthritis
Novo Nordisk A/S n=407
NCT03758638 COMPLETED
Healthy Eating and Active Living Taught at Home (HEALTH) Dissemination & Implementation (D&I)
Washington University School of Medicine n=620
NCT03968224 COMPLETED
Effectiveness of Dapagliflozin for Weight Loss
Centro Medico Nacional Siglo XXI IMSS n=160
NCT01774682 COMPLETED
Kinematics of Obese Patients Perambulation
Centre Hospitalier Universitaire, Amiens n=99
NCT05872620 COMPLETED
A Study of Orforglipron in Adult Participants With Obesity or Overweight and Type 2 Diabetes
Eli Lilly and Company n=1,613
NCT04847557 COMPLETED
A Study of Tirzepatide (LY3298176) in Participants With Heart Failure With Preserved Ejection Fraction (HFpEF) and Obesity: The SUMMIT Trial
Eli Lilly and Company n=731
NCT05931380 COMPLETED
A Study of Once-Daily Oral Orforglipron (LY3502970) in Japanese Adult Participants With Obesity Disease
Eli Lilly and Company n=238
NCT05997576 COMPLETED
A Study of TG103 Injection in Non-diabetic Overweight or Obesity
CSPC Baike (Shandong) Biopharmaceutical Co., Ltd. n=675
NCT05316467 TERMINATED
Weight Management Plus Megestrol Acetate in Early-stage Endometrioid Carcinoma
Xiaojun Chen n=8
NCT04184622 COMPLETED
A Study of Tirzepatide (LY3298176) in Participants With Obesity or Overweight
Eli Lilly and Company n=2,539
NCT01825798 COMPLETED
Treatment of Overweight Induced by Antipsychotic Medication in Young People With Autism Spectrum Disorders (ASD)
Holland Bloorview Kids Rehabilitation Hospital n=60
NCT06396429 COMPLETED
To Compare the Efficacy and Safety of HRS9531 and Placebo in Subjects With Overweight or Obese
Fujian Shengdi Pharmaceutical Co., Ltd. n=567
NCT05132088 COMPLETED
Research Study to Investigate How Well Semaglutide Tablets Taken Once Daily Work in East Asian People Who Are Overweight or Living With Obesity
Novo Nordisk A/S n=201
NCT05412004 COMPLETED
Obstructive Sleep Apnea Master Protocol GPIF: A Study of Tirzepatide (LY3298176) in Participants With Obstructive Sleep Apnea
Eli Lilly and Company n=469
NCT06950138 COMPLETED
Efficacy of Triticum Aestivum Over Vascular Function in Mexican Obese Patients
Coordinación de Investigación en Salud, Mexico n=20
NCT05516953 COMPLETED
Baclofen in Preventing Postoperative Nausea and Vomiting After Bariatric Surgery
Tanta University n=100
NCT04889183 COMPLETED
SeMaglutide and Albuminuria Reduction Trial in Obese Individuals Without Diabetes
University Medical Center Groningen n=125
NCT05929066 COMPLETED
A Study of Retatrutide (LY3437943) in Participants Who Have Obesity or Overweight
Eli Lilly and Company n=2,335
NCT05620641 COMPLETED
Ondansetron and Gabapentin in Preventing Postoperative Nausea and Vomiting After Laparoscopic Sleeve Gastrectomy
Tanta University n=100
NCT00687739 COMPLETED
Prevention of Obesity in Women Via Estradiol Regulation
University of Colorado, Denver n=79
NCT06839664 COMPLETED
A Study of HS-20094 in Chinese Adults With Overweight or Obesity
Jiangsu Hansoh Pharmaceutical Co., Ltd. n=604
NCT05872932 COMPLETED
Outcome of Combined Botulinum Toxin A Injection and Gastric Balloon Implantation in Obesity Treatment
Sebahattin Celik MD n=131
NCT04520256 COMPLETED
Rapid Evaluation of Innovative Intervention Components to Maximize the Health Benefits of Behavioral Obesity Treatment Delivered Online: An Application of Multiphase Optimization Strategy
The Miriam Hospital n=384
NCT05384431 COMPLETED
Can We Achieve 'high-quality' Weight Loss Through Supplementation and Exercise? the TRIM MUSCLE Study
Exerkine Corporation n=51
NCT02514629 COMPLETED
Testosterone, Metformin, or Both, for Hypogonadism in Obese Males
Fundación Pública Andaluza para la Investigación de Málaga en Biomedicina y Salud n=107
NCT04966741 COMPLETED
Setmelanotide in Pediatric Participants With Rare Genetic Diseases of Obesity
Rhythm Pharmaceuticals, Inc. n=12
NCT05607680 COMPLETED
A Study of IBI362 in Participants With Obesity or Overweight
Innovent Biologics (Suzhou) Co. Ltd. n=610
NCT03924193 COMPLETED
Cognitive-Behavioral and Pharmacologic (LDX) Treatment of Binge-Eating Disorder and Obesity: Acute Treatment
Yale University n=141
NCT03574597 COMPLETED
Semaglutide Effects on Heart Disease and Stroke in Patients With Overweight or Obesity
Novo Nordisk A/S n=17,604
NCT03192566 SUSPENDED
Acetaminophen Dosing in Obese Adolescents
Children's National Research Institute n=6
NCT01667783 COMPLETED
Improving Diabetes Through Lifestyle and Surgery
Johns Hopkins University n=15
NCT04844918 COMPLETED
A Study of Tirzepatide (LY3298176) in Participants With Obesity Disease
Eli Lilly and Company n=267
NCT06489457 COMPLETED
The Effects of Semaglutide vs Testosterone Replacement Therapy on Functional Hypogonadism and Sperm Quality in Men With Type 2 Diabetes Mellitus and Obesity
University Medical Centre Ljubljana n=25
NCT02157974 COMPLETED
Liver and Fat Regulation in Overweight Adolescent Girls
University of Colorado, Denver n=92
NCT04660643 COMPLETED
A Study of Tirzepatide (LY3298176) in Participants With Obesity or Overweight for the Maintenance of Weight Loss
Eli Lilly and Company n=783
NCT04657016 COMPLETED
A Study of Tirzepatide (LY3298176) In Participants After A Lifestyle Weight Loss Program
Eli Lilly and Company n=579
NCT03961360 COMPLETED
Effectiveness of Higher Aspirin Dosing for Prevention of Preeclampsia in High Risk Obese Gravida
The University of Texas Health Science Center, Houston n=220
NCT04657003 COMPLETED
A Study of Tirzepatide (LY3298176) in Participants With Type 2 Diabetes Who Have Obesity or Are Overweight
Eli Lilly and Company n=938
NCT05409612 COMPLETED
Trial Assessing the Immunogenicity and Safety of Two Influenza Vaccine Strategies Among Severe Obese Adult Patients
Assistance Publique - Hôpitaux de Paris n=206
NCT04741074 TERMINATED
Effect of Subcutaneous Semaglutide on Kidney Transplant Candidacy
Geisinger Clinic n=15
NCT03047005 COMPLETED
Behavioral and Pharmacologic Treatment of Binge Eating and Obesity: Maintenance Therapy
Yale University n=68
NCT03063606 COMPLETED
Behavioral and Pharmacologic Treatment of Binge Eating and Obesity: Specialist Treatment
Yale University n=31
NCT05024032 COMPLETED
A Study of Tirzepatide (LY3298176) in Chinese Participants Without Type 2 Diabetes Who Have Obesity or Overweight (SURMOUNT-CN)
Eli Lilly and Company n=210
NCT04885634 WITHDRAWN
Semaglutide for the Reduction of Arrhythmia Burden in Overweight AF Patients
Axel Brandes
NCT05667038 COMPLETED
Effect of Probiotics Among Overweight and Obese Saudi Adults
King Saud University n=90
NCT02896192 COMPLETED
Setmelanotide for the Treatment of Early-Onset Pro-Opiomelanocortin (POMC) Deficiency Obesity
Rhythm Pharmaceuticals, Inc. n=15
NCT01027143 COMPLETED
Obesity and Asthma: Nutrigenetic Response to Omega-3 Fatty Acids
Nemours Children's Clinic n=143
NCT03454711 COMPLETED
Functional Magnetic Resonance Imaging (fMRI) Exploration of Neurocognitive Processes Involved in Food Addiction (FA) in Obese Patients: Towards New Phenotypic Markers for an Optimized Care Pathway
Rennes University Hospital n=47
NCT04717726 COMPLETED
Exercise, Milk Thistle, and Lactobacillus to Influence Plasma Bilirubin
Kyle Flack n=42
NCT02527200 COMPLETED
Effect of Liraglutide for Weight Management in Paediatric Subjects With Prader-Willi Syndrome
Novo Nordisk A/S n=56
NCT03693430 COMPLETED
Two-year Research Study Investigating How Well Semaglutide Works in People Suffering From Overweight or Obesity
Novo Nordisk A/S n=304
NCT04605861 COMPLETED
The Efficacy and Safety of Liraglutide on Body Weight Loss in Obese and Overweight Patients
Shanghai Zhongshan Hospital n=414
NCT03287960 COMPLETED
Setmelanotide for the Treatment of Leptin Receptor (LEPR) Deficiency Obesity
Rhythm Pharmaceuticals, Inc. n=15
NCT04074161 COMPLETED
Research Study to Investigate How Well Semaglutide Works Compared to Liraglutide in People Living With Overweight or Obesity
Novo Nordisk A/S n=338
NCT03435458 TERMINATED
Balloon to Induce Labor in Generous Women.
University Hospital, Toulouse n=429
NCT03045341 COMPLETED
Behavioral and Pharmacologic Treatment of Binge Eating and Obesity: Acute Treatment
Yale University n=136
NCT05405244 COMPLETED
Examination of Bromocriptine on Homeostatic and Hedonic Mechanisms of Food Intake in Individuals at High Risk for T2DM
University of North Carolina, Chapel Hill n=55
NCT02367105 COMPLETED
Lifestyle Intervention and Testosterone Replacement in Obese Seniors
VA Office of Research and Development n=83
NCT02417103 TERMINATED
Pretreatment of Patients Expecting Bariatric Surgery With the GLP-1 Analogon Liraglutid
Universitätsklinikum Hamburg-Eppendorf n=2
NCT02664441 COMPLETED
Energy Balance & Weight Loss in Craniopharyngioma-related or Other Hypothalamic Tumors in Hypothalamic Obesity
Seattle Children's Hospital n=42
NCT03720574 TERMINATED
Lorcaserin and Behavioral Modification for Overweight and Obesity Management in Chinese Obese Patients
Kanion & Huawe Medicine Co.,Ltd n=100
NCT02553915 COMPLETED
Omega-3 Fatty Acids for Major Depressive Disorder With High Inflammation: A Personalized Approach
Massachusetts General Hospital n=61
NCT04800172 COMPLETED
The Possible Effects of Roflumilast on Obesity Related Disorders
Tanta University n=66
NCT02675699 COMPLETED
The Optimising Family Engagement in HENRY (OFTEN) Study
University of Leeds n=126
NCT03811574 COMPLETED
STEP 6: Research Study Investigating How Well Semaglutide Works in People Living With Overweight or Obesity
Novo Nordisk A/S n=401
NCT03548987 COMPLETED
Research Study Investigating How Well Semaglutide Works in People Suffering From Overweight or Obesity
Novo Nordisk A/S n=902
NCT02880540 COMPLETED
Dexmedetomidine to Treat Bariatric Surgery-associated Pain
Janelle Vaughns n=26
NCT03548935 COMPLETED
STEP 1: Research Study Investigating How Well Semaglutide Works in People Suffering From Overweight or Obesity
Novo Nordisk A/S n=1,961
NCT03611582 COMPLETED
Research Study to Look at How Well Semaglutide is at Lowering Weight When Taken Together With an Intensive Lifestyle Program
Novo Nordisk A/S n=611
NCT03552757 COMPLETED
Research Study Investigating How Well Semaglutide Works in People With Type 2 Diabetes Suffering From Overweight or Obesity
Novo Nordisk A/S n=1,210
NCT01570829 COMPLETED
Clinical Trial of Safety and Efficacy of New Dosage Schedule for Dietressa Drug in Treatment of Obese Patients
Materia Medica Holding n=331
NCT04678323 WITHDRAWN
Pharmacotherapy for Pediatric Obesity: A Phentermine Clinical Trial
University of Minnesota
NCT03196791 COMPLETED
Compare the Oncological Benefit of Deep Neuromuscular Block in Gastric Cancer Obesity Patient
Korea University Anam Hospital n=196
NCT03480022 COMPLETED
Liraglutide 3mg (Saxenda) on Weight, Body Composition, Hormonal and Metabolic Parameters in Obese Women With PCOS
Woman's n=88
NCT01114451 TERMINATED
Early Versus Delayed Skin Staple Removal Following Cesarean Delivery in the Obese Patient
Prisma Health-Upstate n=292
NCT01644201 TERMINATED
A Study Evaluating the Effects of a High Viscosity Non-starch Polysaccharide (PolyGlycopleX® - PGX®) on Glycemic Control, Cardiometabolic Risk Factors and Weight Loss in Overweight and Obese Type II Diabetics
InovoBiologic Inc. n=100
NCT02635386 COMPLETED
EQW, DAPA, EQW/DAPA, DAPA/MET ER and PHEN/TPM ER in Obese Women With PolycysticOvary Syndrome (PCOS)
Woman's n=119
NCT00696228 COMPLETED
High Fat Diet: Oxidative and Cardiovascular Effects
Vanderbilt University n=144
NCT02868177 COMPLETED
Effect of Totum-63, Active Ingredient of Valedia, on Glucose and Lipid Homeostasis on Subjects With Prediabetes
Valbiotis n=66
NCT03585413 COMPLETED
Impact of a Specific Micronutrient-probiotic-supplement on Fatty Liver of Patients After Mini-Gastric Bypass Surgery
Bonn Education Association for Dietetics r.A., Cologne, Germany n=60
NCT01613664 COMPLETED
Efficiency of TISSEEL for Sleeve Gastrectomy Complications
Centre Hospitalier Universitaire, Amiens n=597
NCT02183935 COMPLETED
Treatment of Morbidly Obese Adolescent With a Duodena-jejunal Liner
University Medical Centre Ljubljana n=22
NCT02918279 COMPLETED
Effect of Liraglutide for Weight Management in Pubertal Adolescent Subjects With Obesity
Novo Nordisk A/S n=251
NCT03419624 TERMINATED
The Potential of Dapagliflozin Plus Exenatide in Obese Insulin-resistant Patients
Universitätsklinikum Hamburg-Eppendorf n=13
NCT02963922 COMPLETED
Effect and Safety of Liraglutide 3.0 mg in Subjects With Overweight or Obesity and Type 2 Diabetes Mellitus Treated With Basal Insulin
Novo Nordisk A/S n=396
NCT02963935 COMPLETED
Effect and Safety of Liraglutide 3.0 mg as an Adjunct to Intensive Behaviour Therapy for Obesity in a Non-specialist Setting
Novo Nordisk A/S n=282
NCT02342899 COMPLETED
Cost Effectiveness of Outpatient Set-up of Automated NIV in Obese Patients With Chronic Respiratory Failure
Guy's and St Thomas' NHS Foundation Trust n=82
NCT00907660 COMPLETED
A Randomized Trial Comparing Two Doses of Portion-Controlled Foods Within a Primary Care Weight Loss Program
Kaiser Permanente n=50
NCT03290846 COMPLETED
Secretin Activates Human Brown Fat and Induces Satiation.
Turku University Hospital n=23
NCT00603902 COMPLETED
BLOSSOM: Behavioral Modification and Lorcaserin Second Study for Obesity Management
Eisai Inc. n=4,008
NCT00856609 COMPLETED
The Effects of Exenatide (Byetta ) on Energy Expenditure and Weight Loss in Nondiabetic Obese Subjects
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) n=150
NCT00624923 COMPLETED
Targeting Inflammation Using Salsalate in CardioVascular Disease
Joslin Diabetes Center n=340
NCT03554525 COMPLETED
Weight Regain After Consumption of Food Supplement and Interventional Diet Program
Instituto de Investigación Hospital Universitario La Paz n=120
NCT03842501 COMPLETED
Effects of the GOLO Weight Management Program With and Without Release Supplement on Weight and Metabolic Parameters in Subjects With Obesity
Golo n=68
NCT02478580 COMPLETED
Armodafinil (Nuvigil), Postoperative Recovery of OSA (Obstructive Sleep Apnea) and Obese Patients
University of Texas Southwestern Medical Center n=67
NCT01535014 COMPLETED
Clinical Trial of Safety and Efficacy of Various Dosage Schedules for Dietressa Drug in Treatment of Obese Patients
Materia Medica Holding n=493
NCT01724099 COMPLETED
Evaluating the Safety and Efficacy of Euiiyin-tang on Obesity
Kyunghee University Medical Center n=149
NCT03516188 COMPLETED
Efficacy of Gaviscon-Advance® in Suppressing Post-supper Acid-pocket and Night-time Acid-reflux in Obese Participants
Universiti Sains Malaysia n=24
NCT02978105 COMPLETED
Effects of Self-conditioning Techniques in Promoting Weight Loss in Patients With Obesity. A Randomized Controlled Trial
University of Turin, Italy n=120
NCT01272219 COMPLETED
Effect of Liraglutide on Body Weight in Non-diabetic Obese Subjects or Overweight Subjects With Co-morbidities: SCALE™ - Obesity and Pre-diabetes
Novo Nordisk A/S n=3,731
NCT01272232 COMPLETED
Effect of Liraglutide on Body Weight in Overweight or Obese Subjects With Type 2 Diabetes: SCALE™ - Diabetes
Novo Nordisk A/S n=846
NCT03336086 COMPLETED
Effect of Weight Reduction on Immunity
Shiraz University of Medical Sciences n=29
NCT00781937 COMPLETED
Comparison of Liraglutide Versus Placebo in Weight Loss Maintenance in Obese Subjects: SCALE - Maintenance
Novo Nordisk A/S n=422
NCT01557166 COMPLETED
Effect of Liraglutide in Obese Subjects With Moderate or Severe Obstructive Sleep Apnoea: SCALE™ - Sleep Apnoea
Novo Nordisk A/S n=359
NCT00955903 COMPLETED
Calorie Restriction and Changes in Body Composition, Disease, Function, and Quality of Life in Older Adults
University of Alabama at Birmingham n=167
NCT02672592 COMPLETED
Effects of Interleukin-1 Beta on Low Testosterone Levels in Men With Obesity and Metabolic Syndrome
University Hospital, Basel, Switzerland n=70
NCT01320722 COMPLETED
Study of Vitamin D and Uric Acid Lowering on Kidney and Blood Vessel Function
Brigham and Women's Hospital n=242
NCT01208558 COMPLETED
Grain Exercise Trial - Whole Grain Versus no Grain With or Without Physiotherapy-promoted Exercise for Waist Loss
Lund University n=105
NCT02857660 COMPLETED
Effect of Whole Body Electromyostimulation and/or Protein Supplementation on Sarcopenic Obesity in 70+
University of Erlangen-Nürnberg Medical School n=100
NCT01601704 TERMINATED
Cardiovascular Outcomes Study of Naltrexone SR/Bupropion SR in Overweight and Obese Subjects With Cardiovascular Risk Factors (The Light Study)
Orexigen Therapeutics, Inc n=8,910
NCT02179151 TERMINATED
Double-Blind, Placebo Controlled, Phase 3 Trial of ZGN-440 (Beloranib) in Obese Subjects With Prader-Willi Syndrome
Zafgen, Inc. n=108
NCT01546727 COMPLETED
Behavioral Treatment for Obese Preschoolers
Children's Hospital Medical Center, Cincinnati n=167
NCT02648360 COMPLETED
Text Messaging for Physical Activity & Healthy Eating
University of Miami n=12
NCT02564445 COMPLETED
Using Social Incentives and Gamification for Weight Loss Promotion
University of Pennsylvania n=196
NCT02129608 COMPLETED
Low Level Laser Treatment (LLLT) and Lorcaserin for Weight Management
Mayo Clinic n=44
NCT01180101 COMPLETED
Effects of Intentional Weight Loss Interventions in Chronic Kidney Disease
The Cleveland Clinic n=37
NCT02832219 COMPLETED
Medium-term Effects of Molecular Hydrogen on Metabolic Fitness in Obesity
Center for Health Sciences, Serbia n=12
NCT02213159 COMPLETED
Dexmedetomidine for Postoperative Analgesia After Bariatric Surgery
American University of Beirut Medical Center n=60
NCT02356016 COMPLETED
Effects of Whole-body Electromyostimulation and Dietary Supplements on "Sarcopenic Obesity"
University of Erlangen-Nürnberg Medical School n=75
NCT02140697 COMPLETED
Efficacy and Safety of Hippophae Rhamnoides L. Leaf Extract on Body Fat
Chonbuk National University Hospital n=80
NCT00940628 COMPLETED
A Study of Xenical (Orlistat) in Overweight and Obese Adolescents
Hoffmann-La Roche n=60
NCT01677923 COMPLETED
Obesity in Children and Adolescents: Associated Risks and Early Intervention
Lithuanian University of Health Sciences n=182
NCT02214108 COMPLETED
Effect of Physical Activity Through Interactive Video Games in Overweight Children
Centro Pediatrico Albina de Patino n=60
NCT01273584 COMPLETED
Metformin in Obese Non-diabetic Pregnant Women
Epsom and St Helier University Hospitals NHS Trust n=450
NCT01043718 COMPLETED
Delivering an Evidence-Based Lifestyle Intervention Via the Internet: A Randomized Controlled Study
University of Pittsburgh n=120
NCT01044147 COMPLETED
Online Counseling to Enable Lifestyle-focused Obesity Treatment in Primary Care
University of Pittsburgh n=360
NCT01934777 COMPLETED
Efficacy and Tolerance of Treatment With DHA, Choline and Vitamin E in Children With Non-alcoholic Steatohepatitis
Bambino Gesù Hospital and Research Institute n=60
NCT01764386 COMPLETED
Method-of-Use Study Assessing the Effect of Naltrexone Sustained Release (SR)/ Bupropion SR on Body Weight and Cardiovascular Risk Factors in Overweight and Obese Subjects
Orexigen Therapeutics, Inc n=242
NCT01568437 COMPLETED
Transversus Abdominis Plane (TAP) Block in Laparoscopic Gastric-bypass Surgery
University Health Network, Toronto n=70
NCT01028976 COMPLETED
Obesity, Inflammation and Oxidative Stress
University of California, Berkeley n=512
NCT01315366 COMPLETED
Hypovitaminosis D : A Link Between Bone/Mineral and Fat/Fuel Metabolism
American University of Beirut Medical Center n=257
NCT01388205 COMPLETED
Trial of a Novel Family-Based Intervention to Increase Outdoor Time and Fitness
National University of Singapore n=285
NCT02516475 COMPLETED
Effects of Zinc Supplementation on Anthropometric Factors, Apelin and Inflammatory Markers in Obese Individuals
National Nutrition and Food Technology Institute n=50
NCT01552642 COMPLETED
An Interactive Web-based Intervention to Achieve Healthy Weight in Young Children
University of Wisconsin, Madison n=77
NCT02137330 COMPLETED
Obalon in Children With Severe Obesity
Bambino Gesù Hospital and Research Institute n=10
NCT02492698 COMPLETED
Changes in Body Adiposity by Dual Probiotic Strains Positively Correlated With Changes in Lp-PLA2 Activity in Overweight Adults
Yonsei University n=120
NCT01794429 COMPLETED
Treatment of Antipsychotic-associated Obesity With a GLP-1 Analogue
Bjorn H. Ebdrup n=45
NCT02108691 COMPLETED
Effect of Intake of Glycin Max (L.) Merr. Peel Extract on Body Fat and Body Weight
Hanyang University n=80
NCT00993278 COMPLETED
Effects of the Atkins Diet Versus a Low Fat Diet on Inflammation
Boston Medical Center n=60
NCT01113996 COMPLETED
Monitoring Patients Who Are Obese Surgery for Gastric By-pass Protein Supplementation and Physical Training (PROMISE)
Assistance Publique - Hôpitaux de Paris n=78
NCT00594399 COMPLETED
Enhancing Fitness in Older Pre-diabetic Veterans
US Department of Veterans Affairs n=302
NCT02410668 COMPLETED
The Effects of Flaxseed Supplement on Weight and Biochemical Factors in Overweight and Obese Subject
National Nutrition and Food Technology Institute n=50
NCT01499485 COMPLETED
Treatment of Metabolic Alkalosis With Acetazolamide. Effect on the Length of Mechanical Ventilation.
Hospital Son Llatzer n=140
NCT01598233 COMPLETED
Effects of Intragastric Balloon on Bone, Metabolic and Respiratory Parameters
Universidade Federal do Rio de Janeiro n=50
NCT01601574 COMPLETED
Weight Loss Study for People With Type 2 Diabetes
Medical University of South Carolina n=563
NCT01467284 COMPLETED
School Worksite Weight Gain Prevention Intervention Study
University of Massachusetts, Worcester n=844
NCT00989339 WITHDRAWN
Effects of Intralipid Versus Olive Oil Infusions on Endothelial Function, Immune Function, Inflammatory Markers
Emory University
NCT01306214 COMPLETED
Safety and Efficacy of BI 10773 as add-on to Insulin Regimen in Patients With Type 2 Diabetes Mellitus
Boehringer Ingelheim n=566
NCT00969267 COMPLETED
The Effect of Auricular Point Stimulation on Obese Women
Taipei City Hospital n=90
NCT01015976 COMPLETED
A Preliminary Comparison of the Blood Levels of Medications in Obese Subjects Compared to Post-Gastric Bypass Subjects
Neuropsychiatric Research Institute, Fargo, North Dakota n=10
NCT01766791 COMPLETED
Resistance Exercise, Muscle Mass, Strength and Body Composition
University of Erlangen-Nürnberg Medical School n=120
NCT02081898 COMPLETED
Effects of Long Term Calorie Restriction on Sphingomyelin and Amino Acids
Yonsei University n=120
NCT01934036 COMPLETED
Obex, a Nutritional Supplement, in Overweight and Obese Spanish Women
Catalysis SL n=92
NCT01764113 COMPLETED
Effect of Mindful Eating on Body Mass Index in Obese Adolescents
Mayo Clinic n=21
NCT00808431 COMPLETED
ST of TN-Salud Con La Familia: Prevent Onset of Ped Obesity
Vanderbilt University n=100
NCT01607177 COMPLETED
Do Text Message Reminders Increase Preoperative Exercise in Obesity Surgery Candidates?
University of Auckland, New Zealand n=102
NCT01249872 COMPLETED
Patients-Controlled Epidural Analgesia After Gastric Bypass for Morbid Obesity Using Morphine-Levobupivacaine Regimens
University of Patras n=96
NCT00942097 COMPLETED
Homeopathic Medication and Nutritional Oriented Diet to Treat Overweight Pregnant Women With Mental Disorder
Edgard Costa de Vilhena n=134
NCT01560130 COMPLETED
State-wide Health Approach to Increase Reach and Effectiveness: Study 2
The Miriam Hospital n=300
NCT01264393 COMPLETED
State-wide Health Approach to Increase Reach and Effectiveness: Study 1
The Miriam Hospital n=500
NCT00990457 COMPLETED
Evaluating the Effects Two Diets Combined With Exercise in Persons With Abdominal Obesity (The SHAPE5 Study)
Johns Hopkins University n=77
NCT00483171 TERMINATED
A 14-Month Study On The Effects Of CP-945,598 For The Prevention Of Weight Regain In Obese Patients
Pfizer n=699
NCT01344161 COMPLETED
Effect of Vitamin D on Metabolic Profile in Overweight or Obese Women
Tehran University of Medical Sciences n=85
NCT00796367 COMPLETED
A Safety and Efficacy Study of VI-0521 to Evaluate the Long Term Treatment of Obesity in Adults With Obesity-Related Co-Morbid Conditions. An Extension Study of Protocol OB-303 (NCT00553787)
VIVUS LLC n=676
NCT01193543 COMPLETED
Effect of Calanus Oli on Intra-abdominal Fat, Glucose Tolerance and Lipids in Man
University of Tromso n=117
NCT01211574 COMPLETED
Pilot Study Testing Professional, Peer, and Mentor Health Coaches for Weight Loss
The Miriam Hospital n=44
NCT00826774 COMPLETED
Improving the Management of Obesity in Primary Care Practice (The Power-UP Trial)
University of Pennsylvania n=390
NCT01546792 COMPLETED
Lifestyle Intervention in Obstructive Sleep Apnoea
Sheffield Teaching Hospitals NHS Foundation Trust n=60
NCT01358890 COMPLETED
Low-Carbohydrate Diet Intervention on Body Weight
Chinese Academy of Sciences n=50
NCT01233349 COMPLETED
Safety and Efficacy of Litramine in Overweight and Obese Subjects
InQpharm Group n=125
NCT00526565 COMPLETED
Randomized Trial of Tapas Acupressure for Weight Loss Maintenance
Kaiser Permanente n=472
NCT01047657 COMPLETED
Effects of Weight Loss in Obese Difficult-to-treat Asthmatics
University of Sao Paulo General Hospital n=33
NCT00994513 COMPLETED
Effect of Alpha Lipoic Acid on Obesity Related Comorbidities
Augusta University n=70
NCT00944138 COMPLETED
8-week Pilot Study of Relaxation for Weight Loss in Adults With Chronic Kidney Disease
Edward Hines Jr. VA Hospital n=20
NCT00434525 COMPLETED
Laparoscopic Sleeve Gastrectomy With and Without Omentectomy
North Texas Veterans Healthcare System n=30
NCT00434655 COMPLETED
Laparoscopic Adjustable Gastric Banding Versus Laparoscopic Sleeve Gastrectomy
North Texas Veterans Healthcare System n=40
NCT00678483 TERMINATED
Long-Term Effect of 10 mg Versus 20 mg Rimonabant in Overweight or Obese Patients
Sanofi n=331
Frequently asked
Common questions about the Obesity landscape
- How many companies are developing Obesity treatments?
- 17 companies have active or registered Obesity programs in TheraRadar's competitive landscape (158 classified trials). The most active are Eli Lilly, Novo Nordisk A/S, and Amgen.
- What mechanisms of action are being developed for Obesity?
- 11 distinct mechanisms of action appear across the Obesity pipeline, including GLP1R, GLP-1/GIP, AMYLIN, GLP-1 receptor agonist, and GLP-1/Amylin.
- What is the most crowded mechanism in Obesity?
- GLP1R is the most contested mechanism in Obesity, with 30 programs mapped to it.
- Are there upcoming Obesity clinical readouts or FDA decisions?
- Near-term Obesity catalysts include VRB-101 (data readout, Jul '26); LY4086940 (data readout, Aug '26); ecnoglutide tablets (data readout, Aug '26). Dates combine estimated trial primary-completion readouts and confirmed FDA decision dates.
- Where does TheraRadar's Obesity landscape data come from?
- Programs are derived from industry-sponsored ClinicalTrials.gov registrations (2008–present) and classified by mechanism of action using a curated rule set plus an LLM pipeline. Every cell links to its underlying trials, so each program is verifiable.
- Is the Obesity heatmap free to use?
- Yes — viewing and searching the Obesity heatmap is free. A TheraRadar Pro subscription adds advanced filters, row/column selection, and one-click export to PowerPoint, PDF, and CSV.
How this is built — methodology & limits
These grids are only as good as the data and the classification behind them — so here is exactly what goes in, what stays out, how every assignment is made, and where the limits are.
Where the data comes from
Every heatmap is built from the public ClinicalTrials.gov registry, via its official API — interventional drug and biologic trials with a start date of 2008 or later. The master index holds over 145,000 trials and is refreshed weekly (see the “updated” date on this page). A disease landscape draws only from the active, Phase 1–3, industry-sponsored slice of that index.
- In scope: industry-sponsored trials in Phase 1, 2, or 3, with an active status (recruiting, active-not-recruiting, not-yet-recruiting, or enrolling by invitation). Phase 4 sits in the index but is left out of the landscapes.
- Filtered out: deeply stale programs (a primary completion date more than two years past with no update to completed or terminated); basket trials and incidental mentions (a trial counts toward a disease only when that disease is genuinely the subject of study — not a secondary cohort, an organ-of-origin overlap, or a passing mention); and healthy-volunteer studies.
We do not exclude trials by sponsor geography. Where a sponsor is based in China, the program is flagged on the page rather than hidden, so you can weigh it yourself. An automated test fails the weekly refresh if the underlying index is more than 14 days old, so a published grid is never built on a stale index.
How a trial is matched to a disease
Matching uses a structured medical ontology, not keyword guessing, and is designed so that no trial is ever silently dropped — every trial that clears the filters gets a classification, even if that is just “Other.” It runs as an ordered sequence of steps, stopping at the first that applies:
- Healthy-volunteer studies are set aside as non-disease trials.
- Ontology match — each tracked disease is linked to its official identifiers in the standard medical taxonomy (MeSH), so a trial can be matched even when its text uses a synonym.
- Curated disease patterns — a hand-maintained library of over 150 disease-name patterns covers the more granular indications across oncology, hematology, infectious disease, cardiometabolic, immunology, and neuropsychiatry.
- Basket guard — a trial matching four or more distinct diseases, or carrying explicit basket language (“tumor-agnostic,” “all solid tumors,” “pan-cancer”), is grouped into a single advanced-solid-tumor category rather than over-counted across every cancer it touches.
- Therapeutic-area roll-up — a trial with no specific match, but which the taxonomy still places under a broad area, is assigned to that area (“Oncology — other,” “Immunology — other,” …), checking cancers first so a site-specific tumor isn’t filed under its anatomical system.
A “drop-if-parent-present” rule keeps a generic name from drowning out a subtype: a trial matching both lupus and lupus nephritis is reported only as lupus nephritis. Internal abbreviations are translated to the plain disease names used across the site (for example, “CRC” becomes “Colorectal Cancer”), and the same classifier is shared by every heatmap, so the same trial always maps to the same disease wherever it appears.
How a drug is matched to its mechanism
Mechanism of action is the hardest part to get right, so it is assigned in layers — leaning on curated and public data first, with AI as a last resort:
- Curated rulebook (first). A rulebook we maintain — over 600 drug-to-mechanism rules — is checked first, matching on drug names, trial acronyms, sponsor trial identifiers, and intervention lists. First match wins, which stops a combination trial from being counted several times.
- Public molecular-target data. Where no rule applies, each intervention’s target is looked up in a public target database, with verbose or gene-symbol labels normalized into consistent short forms so one target isn’t split across several columns.
- Standard-of-care backbones. A small set of rules recognizes common combination scaffolds (checkpoint-inhibitor monotherapy, standard chemotherapy regimens, established standard-of-care agents) so they aren’t mistaken for the experimental arm.
- AI as a last resort, then cross-checked. Only for genuinely opaque sponsor code-names that none of the first three steps can resolve do we ask an AI model to propose a mechanism — applied only above a fixed confidence bar, then automatically cross-checked against the sponsor’s own pipeline page. Where AI and the sponsor agree, the program is marked sponsor-verified. Where they contradict, the label is discarded entirely — not shown, not counted.
New mechanism rules are independently double-verified before they’re trusted — a second, adversarial pass set up to disprove the first — and each is checked so it can’t mislabel an unrelated trial. Drugs whose mechanism isn’t publicly disclosed are shown openly as “Emerging — not yet disclosed” rather than guessed at: for a tool meant to support real decisions, “we don’t yet know” is a more trustworthy answer than a confident guess.
Where AI is used — and where it isn’t
The disease and mechanism matching above is driven first by deterministic rules and public ontologies, not AI. AI plays three bounded, disclosed roles: (1) an optional extra check that a trial genuinely studies the disease, on top of the ontology match; (2) inferring a trial’s treatment setting on the competitive grids when the rules don’t cover it, only above a fixed confidence bar; and (3) the last-resort mechanism step above, always cross-checked against the sponsor’s disclosures. Wherever an AI label reaches a cell, the page marks it (⚙️ or ✅) — AI is never the silent, sole source of what you see.
What the on-page markers mean
- ✅ Sponsor-verified — AI proposed the mechanism and it matched the sponsor’s own pipeline page. High-trust.
- ⚙️ AI-classified — AI proposed it above the confidence bar but it has not yet been cross-checked against the sponsor. Useful; verify before citing. It never means a person reviewed it.
- ⚡ First-in-class — the mechanism hasn’t appeared in any other disease landscape we’ve built. This reflects the scope of landscapes published so far (the tooltip lists exactly which were scanned), not an absolute claim about the whole market.
- 🌱 First-in-indication — the only program competing on that mechanism within this disease.
- 🆕 NME candidate — the interventions match no drug in our approved-drug index, suggesting a new molecular entity. The index is incomplete — a signal, not a regulatory fact.
- 🔗 Combination · 👶 Pediatric · 🔥 Hot (readout within six months) · ⏳ Stale (completion date passed but still marked active — often a stalled program).
Sponsor names are resolved through a curated parent/subsidiary map; unrecognized sponsors appear under their raw registry name. The registry records the sponsor at a trial’s inception, so names are as originally filed and may not reflect later acquisitions. To keep large grids legible, mechanisms with a single program are listed separately rather than crowding the main grid, and very small players are listed below it — presentation choices only; nothing is removed from the underlying counts.
How we score programs — “what’s about to move”
Each program carries a 0–100 score that deliberately ranks imminence over raw stage — the most decision-relevant signal on a competitive grid. It is the sum of:
- Clinical phase — up to 40 points (Phase 3 = 40, Phase 2 = 25, Phase 1 = 10).
- Readout proximity — up to 60 points (next readout <6 months = 60, 6–12 months = 45, 1–2 years = 30, distant = 5).
- Stale penalty — the score is halved if a trial is past its expected readout but still listed as active.
Cell colour on the grid is driven by this score, so a Phase 2 program about to read out can — correctly — outrank a dormant Phase 3 one. It answers “what’s about to move,” not just “what’s furthest along.”
What each grid plots
- Indication landscape (this page) — one disease — companies (rows) × mechanism of action (columns): who is competing, and on what mechanism.
- Company portfolio — one company — diseases (rows) × mechanism (columns): where it is active, and what it is betting on.
- MOA platform — one mechanism family — drugs (rows) × diseases (columns): who is working on this class, and where.
- Competitive landscape — one disease — mechanism (rows) × clinical setting (columns), aggregated across companies; setting columns are tailored per disease (e.g. lines of therapy in oncology; biologic-naïve vs. biologic-experienced in IBD).
What we don’t claim
- First-in-class is editorial, not absolute — “not seen in the landscapes we’ve built,” not “novel across the industry.”
- NME candidate is a signal, not a filing — absent from our (incomplete) approved-drug index.
- Disease matching is automated and not exhaustively validated per disease — ontology and pattern matching can occasionally include or miss a trial.
- AI-classified mechanisms are machine-proposed — unconfirmed unless they also carry ✅.
- Sponsor names are as-filed and may lag current ownership.
- Grids are as fresh as their last rebuild from the weekly index — no faster continuous refresh is claimed.
Data: ClinicalTrials.gov v2 API + FDA Drugs@FDA (approved-drug index). Spot an error? [email protected].
Data: ClinicalTrials.gov · Trials registered 2008 onwards · Industry sponsors only